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A B S T R A C T
Background
Fatigue is a prevalent and burdensome symptom for patients with incurable cancer receiving cancer treatment with palliative intent and
is associated with reduced quality of life. Psychosocial interventions seem promising for management of fatigue among cancer patients.
Objectives
To assess the effects of psychosocial interventions for fatigue in adult patients with incurable cancer receiving cancer treatment with
palliative intent.
Search methods
We searched the following databases: CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, and seven clinical trial registries; we
also searched the reference lists of articles. The date of our most recent search was 29 November 2016.
Selection criteria
We included randomised controlled trials that compared psychosocial interventions in adults aged 18 years or over undergoing cancer
treatment with palliative intent for incurable cancer versus usual care or other controls. Psychosocial interventions were defined as
various kinds of interventions provided to influence or change cognitions, emotions, behaviours, social interactions, or a combination
of these. Psychosocial interventions of interest to this review had to involve at least two interactions between the patient and the care
provider in which the care provider gave the patient personal feedback concerning changes sought by these interventions. We included
trials that reported fatigue as an outcome of interest.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. Two review authors independently considered trials for inclusion
in the review, assessed risk of bias, and extracted data, including information on adverse events. We assessed the quality of evidence
using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) and created a ’Summary of findings’ table.
Main results
We identified 14 studies (16 reports) that met inclusion criteria for this review and involved 3077 randomised participants in total.
Most of these studies included a mixed sample of participants; we obtained data for the subset of interest for this review (diagnosis of
incurable cancer and receiving cancer treatment) from the study investigators of 12 studies, for which we included 535 participants
in the subset meta-analysis for fatigue post intervention. Researchers investigated a broad range of psychosocial interventions with
different intervention aims and durations. We identified sources of potential bias, including lack of description of methods of blinding
and allocation concealment and inclusion of small study populations.
Findings from our meta-analysis do not support the effectiveness of psychosocial interventions for reducing fatigue post intervention
(standardised mean difference (SMD) -0.25, 95% confidence interval (CI) -0.50 to 0.00; not significant; 535 participants, 12 studies;
very low-quality evidence). First follow-up findings on fatigue suggested benefit for participants assigned to the psychosocial intervention
compared with control (SMD -0.66, 95% CI -1.00 to -0.32; 147 participants, four studies; very low-quality evidence), which was not
sustained at second follow-up (SMD -0.41, 95% CI -1.12 to 0.30; not significant; very low-quality evidence).
Results for our secondary outcomes revealed very low-quality evidence for the efficacy of psychosocial interventions in improving
physical functioning post intervention (SMD 0.32, 95% CI 0.01 to 0.63; 307 participants, seven studies). These findings were
not sustained at first follow-up (SMD 0.37, 95% CI -0.20 to 0.94; not significant; 122 participants, two studies; very low-quality
evidence). Findings do not support the effectiveness of psychosocial interventions for improving social functioning (mean difference
(MD) 4.16, 95% CI -11.20 to 19.53; not significant; 141 participants, four studies), role functioning (MD 3.49, 95% CI -12.78 to
19.76; not significant; 143 participants, four studies), emotional functioning (SMD -0.11, 95% CI -0.56 to 0.35; not significant; 115
participants, three studies), or cognitive functioning (MD -2.23, 95% CI -12.52 to 8.06; not significant; 86 participants, two studies)
post intervention. Only three studies evaluated adverse events. These studies found no difference between the number of adverse events
among participants in the intervention versus control group.
Using GRADE, we considered the overall quality of evidence for our primary and secondary outcomes to be very low. Therefore, we
have very little confidence in the effect estimate, and the true effect is likely to be substantially different from the estimate of effect.
Limitations in study quality and imprecision due to sparse data resulted in downgrading of the quality of data. Additionally, most studies
were at high risk of bias owing to their small sample size for the subset of patients with incurable cancer (fewer than 50 participants
per arm), leading to uncertainty about effect estimates.
Authors’ conclusions
We found little evidence around the benefits of psychosocial interventions provided to reduce fatigue in adult patients with incurable
cancer receiving cancer treatmentwith palliative intent. Additional studies with larger samples are required to assess whether psychosocial
interventions are beneficial for addressing fatigue in patients with incurable cancer.
P L A I N L A N G U A G E S U M M A R Y
Psychological therapies to reduce tiredness in patients with incurable cancer
Background
Patients with incurable cancer often experience tiredness (fatigue) during cancer treatment. Psychological therapies may help to reduce
this symptom. Tiredness in cancer patients receiving cancer treatment may be treated with psychological therapies aimed at influencing
or changing thoughts, emotions, behaviours, social interactions, or a combination of these (e.g. cognitive-behavioural therapies,
supportive-expressive group therapies). This review looked at how effective psychological therapies are in reducing tiredness in patients
with incurable cancer receiving cancer treatment.
Study characteristics
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In November 2016, we searched for clinical trials looking at psychological therapies in patients with incurable cancer receiving cancer
treatment. We found 14 small studies of very low quality reporting data on tiredness outcomes, 12 of which provided data for analyses.
A limited number (three studies) reported results about side effects; these studies investigated a psychological therapy combined with
medication.
Key findings
Review authors found no support for the effectiveness of psychological therapies in reducing tiredness when assessed directly following
the intervention. Very low-quality evidence suggests that psychological therapies may improve physical functioning directly after the
intervention and may improve tiredness at first follow-up. Evidence shows no support for the effectiveness of psychosocial therapies
in improving other domains of functioning. Limited evaluation of potential harm suggests no differences in side effects between
patients receiving psychological therapy and those given usual care. Limited good quality evidence allows no conclusions on the use
of psychological therapies in people with incurable cancer. Larger, high-quality trials are needed to find out whether psychological
therapies help reduce tiredness for people with incurable cancer during cancer treatment.
Quality of the evidence
We rated the quality of study evidence using four levels: very low, low, moderate, and high. Very low-quality evidence means that we
are very uncertain about the results. High-quality evidence means that we are very confident in the results. Included studies had design
problems and included a very small number of participants. Therefore, the quality of the evidence in this review is very low, and results
of this review should be interpreted with caution.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Psychosocial interventions compared with control intervention for fatigue during cancer treatment with palliative intent
Patient or population: pat ients with incurable cancer receiving cancer treatment with palliat ive intent
Settings: university-af f il iated hospitals, cancer centres, public hospitals
Intervention: psychosocial intervent ion
Comparison: usual care or control condit ion (not a psychosocial intervent ion)




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Fatigue Not known Not known Fatigue in the psychoso-
cial intervent ions group
was lower than in the
control group (SMD -0.





Physical functioning Not known Not known Physical funct ioning in
the psychosocial in-
tervent ions group was
higher (SMD 0.32 , 95%





An SMD of 0.32 repre-
sents a small ef fect size,
with the upper end of the
CI suggest ing this may
be clinically signif icant
for some people
Social functioning Not known Not known Social funct ioning in the
psychosocial interven-
t ions group was higher






Role functioning Not known Not known Role funct ioning in the
psychosocial interven-
t ions group was higher





















































































































Emotional functioning Not known Not known Emotional funct ioning in
the psychosocial in-
tervent ions group was
lower (SMD -0.11 , 95%





Cognitive functioning Not known Not known Cognit ive funct ioning in
the psychosocial in-
tervent ions group was






Adverse events See comment See comment Not est imable No data available for
meta-analysis.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; MD: mean dif ference; SMD: standardised mean dif ference
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close the est imate of ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once: unclear risk of select ion bias.
















































































































B A C K G R O U N D
This review is based in part on suggested wording from the
Cochrane Pain, Palliative and Supportive Care Review Group (Pa-
PaS CRG).
Description of the condition
According to theWorldHealth Organization, palliative care is “an
approach that improves the quality of life of patients and their
families facing the problem associated with life-threatening illness,
through the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of pain
and other problems, physical, psychosocial and spiritual” (WHO
2002). For a long time, cancer treatment with palliative intent for
patients with incurable cancer was considered to represent the ter-
minal phase, reflecting the last months or year before an expected
death. However, owing to advances in the medical treatment of
cancer, more patients with incurable cancer receiving cancer treat-
ment with palliative intent can expect to be chronically ill for an
extended period of years (Italiano 2008; Miller 2008). This leads
to ambiguous medical prognoses: Patients with incurable cancer
may be sick enough to die but could also live for many years
(Lynn 2003). Nowadays, it is common to distinguish three stages
of cancer treatment with palliative intent (Wanrooij 2010). The
first phase - disease palliation - has the aim of reducing disease
activity to improve survival time and quality of life. The second
phase - symptom palliation - primarily aims to prevent and treat
symptoms to improve quality of life. The last phase - terminal
palliation - focuses on quality of life and quality of dying. The cur-
rent review will focus on patients with incurable cancer receiving
cancer treatment aimed at disease palliation (phase 1) or receiving
cancer treatment aimed at disease palliation combined with symp-
tom palliation (phase 1 and 2). This implies that patients need to
receive some form of cancer treatment.
Fatigue is one of the symptoms most commonly reported by pa-
tients receiving cancer treatment with palliative intent (Barnes
2002); prevalence rates up to 99% have been reported (Butt 2008;
Hauser 2008; Radbruch 2008; Stone 2008; Teunissen 2007). Fa-
tigue is frequently cited among the most distressing symptoms
(Butt 2008; Hofman 2007; Paiva 2013) and is associated with
reduced quality of life, poor performance status, and difficulty
in performing daily activities (Butt 2008; Hauser 2008; Tanaka
2002). Many factors are likely to contribute to fatigue in patients
with incurable cancer receiving cancer treatment with palliative
intent. Fatigue could result from the underlying disease itself, as
well as from cancer treatments received by patients. Psychosocial
factors (e.g. sleeping problems, mood disturbances such as depres-
sion and anxiety) can also contribute to fatigue (Peters 2014).
Fatigue can be defined and measured in various ways, and no con-
sensus has been reached about the definition of fatigue in can-
cer patients (Minton 2009; Minton 2013). Cancer-related fatigue
(CRF) is the term that is used most widely to describe this symp-
tom. TheNational Comprehensive Cancer Network (NCCN) de-
fines CRF as “a distressing, persistent, subjective sense of physical,
emotional and/or cognitive tiredness or exhaustion related to can-
cer or cancer treatment that is not proportional to recent activity
and interferes with usual functioning” (Mock 2000). A simpler
distinction between a subjective lack of energy (symptom) and a
confirmable decrease in strength over time (physical or muscular
weakness) has been made (Stone 1999). The most simplified way
to identify fatigue is to ask patients whether they feel fatigued or
tired. We will use the NCCN definition of fatigue for this review.
However, we will also include studies with tiredness, weakness,
lack of energy, or exhaustion as an outcome of interest. According
to NCCN guidelines, fatigue should be measured by self-report
instruments with established cut-off scores (Mock 2000); how-
ever, we will also include studies that measure fatigue via other
self-report instruments.
Efforts to manage fatigue during cancer treatment with pallia-
tive intent for patients with incurable cancer should focus first on
identifying and treating somatic causes. Often, no specific somatic
cause of fatigue can be identified other than the underlying dis-
ease itself or the cancer treatments patients receive. In these sit-
uations, management of fatigue usually involves multiple strate-
gies, which can be divided into pharmacological and non-phar-
macological interventions. Pharmacological interventions include
stimulant drugs, corticosteroids, erythropoietic agents, and antide-
pressants. A Cochrane review focusing on pharmacological inter-
ventions for fatigue concluded that no recommendation could be
given for a specific drug treatment for fatigue in palliative care pa-
tients (Mücke 2015). Non-pharmacological interventions include
both psychosocial interventions and physical activity. Psychosocial
interventions are the focus of this review and will be explained
further in the next section. The role of physical activity/exercise
in the management of fatigue during and after cancer treatment
is supported by evidence from a Cochrane review (Cramp 2012).
However, it remains unclear whether exercise is effective for pa-
tients receiving cancer treatment with palliative intent. Only a few
included randomised controlled trials focused on this particular
patient group.
Description of the intervention
Psychosocial interventions seem promising for management of fa-
tigue among patients with incurable cancer. For this review, psy-
chosocial interventions are defined as various kinds of interven-
tions provided to influence or change cognitions, emotions, be-
haviours, social interactions, or a combination of these, to achieve
better mental health and/or fewer problems, for example, less fa-
tigue. Such interventions may include cognitive-behavioural ther-
apy, coping skills training, motivational therapy, mindfulness-
based stress reduction, and psychoeducational or educational ther-
apies, which may be combined with mind-body elements such as
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yoga, relaxation breathing, or progressive muscle relaxation. Psy-
chosocial interventions of interest for this review involve system-
atic treatment with at least two interactions between patient and
care provider in which the care provider gives the patient personal
feedback concerning changes sought by these interventions. We
will exclude exercise interventions that are primarily aimed at in-
creasing physical fitness or level of physical activity.
How the intervention might work
Although various interventions aimed at CRF can be labelled as
psychosocial, most draw techniques from cognitive therapies, be-
havioural therapies, and educational theories. Psychosocial inter-
ventions usually include a rationale or framework for therapy and
collaborative goal setting (Peyrot 2007). Education about disease
and an explanation of the role of behaviours, beliefs, and emo-
tions in disease and symptoms are common elements of therapy
(Authier 1975). In addition, establishing a therapeutic alliance be-
tween therapist and patient is a key component of a psychosocial
intervention (Frank 1990; Martin 2000; Orlinsky 2004), which
consists of an emotional bond, agreement on goals, and active col-
laboration (Bordin 1979; Gaston 1990).
Generally, psychosocial interventions are based on the assumption
that thoughts, feelings, and actions are interconnected and can
influence fatigue and its consequences. During the intervention,
patients learn to change thoughts, actions, or feelings in relation to
symptoms. Psychosocial interventions differ in terms of assump-
tions made about the mechanisms responsible for the change in
fatigue brought on by the intervention. Assumed mechanisms of
change are different for each intervention, depending on the the-
oretical models underpinning them. Psychosocial interventions
can use one or a combination of techniques or treatment meth-
ods to influence symptoms and their consequences (Peyrot 2007).
One mechanism for reducing fatigue consists of cognitive restruc-
turing as used in cognitive therapies (Beck 1970; Beck 1976) to
change dysfunctional beliefs (e.g. catastrophising, feeling helpless
with respect to fatigue) and to encourage patients to develop more
helpful beliefs (Beck 2011). This approach is thought to reduce
symptoms or change negative emotional states that worsen symp-
toms like fatigue. Another possible mechanism for reducing fa-
tigue is behaviour modification (Bandura 1969), which can be
provided to change behavioural responses to fatigue (e.g. resting
when fatigued). Influencing these behavioural patterns by, for ex-
ample, gradually increasing physical activity can reduce symptoms
and enhance self-efficacy (Bandura 1997). These are only exam-
ples of assumedmechanisms; other potentially effective techniques
and treatment methods with specific therapeutic mechanisms re-
sponsible for CRF reduction are available, such as yoga and (psy-
cho)educational therapies (see also the American Society of Clin-
ical Oncology (ASCO) clinical practice guidelines; Bower 2014).
Although research has provided empirical support for the efficacy
of psychosocial interventions for fatigue (irrespective of the pres-
ence of a medical condition), knowledge about the therapeutic
mechanisms of these interventions is lacking. Limited work has
been done in the field of cognitive-behavioural therapy (CBT) for
patients with medically unexplained fatigue (i.e. chronic fatigue
syndrome (CFS)).Mediation analysis of CBT forCFS has revealed
that changes in both beliefs and behaviours canmediate the effects
of CBT (Chalder 2015; Wiborg 2011; Wiborg 2012). Mediation
analysis of CBT for patients with multiple sclerosis shows that the
decrease in fatigue may be explained by a change in beliefs about
fatigue (Knoop 2012). The scarcity of knowledge about therapeu-
tic mechanisms is even more evident for interventions that reduce
fatigue in patients with cancer. Although CBT was found to be
effective for reducing post-cancer fatigue (Gielissen 2006) and is
now recommended in ASCO clinical practice guidelines for can-
cer-related fatigue (Bower 2014), the mechanisms of change re-
main unknown, and effects on fatigue have not been shown to
be mediated by an increase in objective physical activity or fitness
(Gielissen 2012; Prinsen 2013). To permit unequivocal conclu-
sions about the therapeutic mechanisms of psychosocial interven-
tions that may produce a reduction in fatigue, further research is
needed.
Why it is important to do this review
Advances in medical treatment for patients with incurable cancer
have led to prolonged survival. Maintaining quality of life is an im-
portant goal of cancer treatment with palliative intent. Fatigue is
not only a prevalent symptom, it is also a factor that affects patient
quality of life. A previous Cochrane review (Goedendorp 2009)
investigated the effectiveness of psychosocial interventions among
adult cancer patients receiving cancer treatment. However, few of
the randomised controlled trials (RCTs) identified for this review
included only patientswith incurable cancer receiving cancer treat-
ment with palliative intent, and the review did not analyse sepa-
rately the effectiveness of psychosocial interventions for fatigue in
these patients. The current review will replace Goedendorp 2009
and will differ by focusing exclusively on fatigue in patients with
incurable cancer.Our current reviewwill aid oncologists providing
cancer treatment with palliative intent to inform patients about
evidence-based psychosocial interventions for fatigue.
O B J E C T I V E S
To assess the effects of psychosocial interventions for fatigue in
adult patients with incurable cancer receiving cancer treatment
with palliative intent.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs). We re-
quired full journal publication, with the exception of online clini-
cal trial results, summaries of otherwise unpublished clinical trials,
and abstracts with sufficient data for analysis.
Types of participants
We included studies of adult patients (18 years of age and older)
with a diagnosis of incurable (advanced or metastatic) cancer in
which participants received some form of disease-focused treat-
ment, such as chemotherapy, hormonal therapy, targeted ther-
apy, immunotherapy, surgery, and/or radiation therapy. For stud-
ies with a mixed sample of participants with curable or incurable
cancer and/or receiving cancer treatment or not receiving cancer
treatment, we included only participants with incurable cancer
and receiving cancer treatment. We contacted study authors to
request data or results when the study did not report separate in-
formation on cancer diagnosis and/or treatment. If separate data
could not be provided for the subset of participants of interest
to this review, or if study authors did not respond to requests for
information after two reminders, we included the study only if in-
vestigators reported that at least 80% of participants had incurable
cancer and were receiving cancer treatment. We excluded studies
in which patients received terminal care (i.e. hospice or end-of-
life care).
Types of interventions
We included studies that compared a broad range of psychoso-
cial interventions versus usual care or control conditions (no psy-
chosocial intervention). These interventions included psychother-
apy, psychoeducation, and support group programmes, as well
as elements such as cognitive restructuring, changing in coping
strategies, self-help or self-care, relaxation, energy conservation,
and stress management. Psychosocial interventions could be given
individually or in groups, and by care providers from different
professions, such as psychologists or nurses. We included only
psychosocial interventions involving systematic treatment with at
least two contacts between patient and care provider in which per-
sonal feedback was given concerning changes the patient was try-
ing to achieve. For example, during the first session, a care provider
might advise a patient to change coping behaviours to reduce fa-
tigue, whilst in subsequent sessions, discussion may focus on pa-
tient progress and feedback on patient behaviours. We excluded
studies in which interventions were aimed exclusively at exercise.
Types of outcome measures
Studies used a variety of outcome measures. Included studies re-
ported fatigue, tiredness, weakness, lack of energy, lack of vitality,
or exhaustion as an outcome of interest. Fatigue could be assessed
by specific validated fatigue questionnaires with multiple items or
by other self-report methods. Examples of the latter include one
or more items on fatigue inserted as part of a quality of life in-
strument, a numerical rating scale (NRS), a visual analogue scale
(VAS), or assessment items included as part of a symptom list and
scored as ‘present’ or ‘absent’. Secondary outcomes included phys-
ical, social, role, emotional, and cognitive functioning assessed by
a suitable instrument such as the European Organisation for Re-
search and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) or the Short-Form Health Survey.
We measured adverse events of psychosocial interventions as ab-
sent or present. We have provided a narrative description of these
effects. In addition, we analysed measures of function when used
as an outcome measure in studies.
Primary outcomes
• Fatigue post intervention (alternative terms: tiredness,
weakness, lack of energy, lack of vitality, exhaustion)
Secondary outcomes
• Fatigue (first and second follow-up)
• Physical functioning (post intervention and at first and
second follow-up)
• Social functioning (post intervention)
• Role functioning (post intervention)
• Emotional functioning (post intervention)
• Cognitive functioning (post intervention)
• Adverse events of psychosocial interventions (post
intervention)
Search methods for identification of studies
Electronic searches
We searched the following databases without language or date
restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (via Cochrane Register of Studies Online (CRSO);
searched 29 November 2016) in the Cochrane Library.
• MEDLINE (via Ovid) 1946 to November week 3, 2015.
• Embase (via Ovid) 1974 to 2016 November 29.
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature) 1982 to November 2016.
• PsycINFO (via Ovid) 1806 to November week 3, 2016.
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We used medical subject headings (MeSH) or equivalent and text
word terms. When appropriate, we exploded MeSH terms and
applied theCochrane filter for identification of RCTs, as published
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We have provided search strategies in Appendix
2, Appendix 3, Appendix 4, Appendix 5, and Appendix 6.
Searching other resources
We searched the metaRegister
of controlled trials (mRCT) (www.controlled-trials.com/mrct),
clinicaltrials.gov (www.clinicaltrials.gov), the World Health Or-
ganization (WHO) International Clinical Trials Registry Plat-
form (ICTRP) (http://apps.who.int/trialsearch/), the Australian
New Zealand Trials Registry (http://www.anzctr.org.au/), the In-
ternational Standard Randomized Controlled Trials Number (IS-
RCTN) register (http://www.isrctn.com/), the University hospital
Medical Information Network (UMIN) Clinical Trials Registry (
http://www.umin.ac.jp/ctr/), and the Netherlands Trial Register (
http://www.trialregister.nl/trialreg/index.asp), using the keywords
‘cancer’ and ‘fatigue’ to identify additional completed or ongoing
studies. In addition, we checked relevant reviews and reference
lists of retrieved articles for additional studies, and we performed
citation searches on key articles. When necessary, we contacted
study authors for additional information.
Data collection and analysis
Selection of studies
Two review authors (HP, MP) independently determined eligibil-
ity by reading the abstract of each study identified by the search.
These review authors independently eliminated studies that clearly
did not satisfy inclusion criteria and obtained full copies of remain-
ing studies. The same two review authors read these studies inde-
pendently to select relevant studies; in the event of disagreement,
a third review author adjudicated (HK). We did not anonymise
the studies before assessment. We included a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
chart, which shows the status of identified studies (Moher 2009),
as recommended in Part 2, Section 11.2.1, of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Data extraction and management
Two review authors (HP, MP) independently extracted data using
a standard form and checked for agreement before entering data
into Review Manager (RevMan 2014). We included information
about the following.
Participant characteristics
• Demographic characteristics such as age and gender
• Disease characteristics such as cancer diagnosis and cancer
treatment
• Inclusion/exclusion criteria for participation in study
Psychosocial intervention characteristics (for each study
arm)
• Nature, type of delivery, and content of the intervention
and control condition
• Time point of delivery of intervention in relation to cancer
treatment (during or after)
• Duration of the intervention and total number of sessions
• Description and number of intervention providers
• Duration and nature of training and supervision given to
intervention providers
• Participant adherence and contamination
• Intervention provider treatment integrity and existence of
treatment protocol
Methods and outcomes
• Random sequence generation
• Allocation concealment
• Incomplete outcome data (quantity, nature, and handling
of missing data)
• Size of the study and power calculation
• Blinding of outcome assessors
• Quality of the control condition
• Equality of treatment expectations
• Therapist and/or researcher allegiance
• Key outcomes and measurement instruments used to assess
fatigue
• Adverse events of the psychosocial intervention
• Timing, frequency, and duration of follow-up for each
outcome
We collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
collected characteristics of included studies in sufficient detail to
populate theCharacteristics of included studies table.We included
in the Characteristics of ongoing studies table a study authored
and co-authored by five of the review authors.
Assessment of risk of bias in included studies
Two review authors (HP, MP) independently assessed risk of bias
for each study, using the criteria outlined in theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and
adapted from those used by the Cochrane Pregnancy and Child-
birth Group. We resolved disagreements by discussion. We com-
pleted a ’Risk of bias’ table for each included study using the ’Risk
of bias’ tool in RevMan (RevMan 2014).
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We assessed the following for each study.
• Random sequence generation (checking for possible
selection bias): We assessed the method used to generate the
allocation sequence as having low risk of bias (any truly random
process; e.g. random number table; computer random number
generator) or unclear risk of bias (method used to generate
sequence not clearly stated). We excluded studies using a non-
random process (e.g. odd or even date of birth, hospital or clinic
record number).
• Allocation concealment (checking for possible selection
bias): The method used to conceal allocation to interventions
before assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We assessed methods as having low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes) or unclear risk
of bias (method not clearly stated). We excluded studies that did
not conceal allocation (e.g. open list).
• Blinding of outcome assessment (checking for detection
bias): This is usually assessed by looking at the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. However, in RCTs
investigating effects of psychosocial interventions, it is impossible
to blind care providers to the intervention they are giving to
participants. It is also nearly impossible to blind participants to
the intervention to which they were assigned. We judged risk of
bias in blinding of outcome assessment on whether measures
were administered and collected by an assessor who was blind to
treatment allocation. We assessed methods as having low risk of
bias (study states that outcome assessment was blinded and
describes the method used to achieve blinding); unclear risk of
bias (study states that it was blinded but does not provide an
adequate description of how this was achieved); or high risk of
bias (studies states that outcome assessors were not blinded).
• Incomplete outcome data (checking for possible attrition
bias due to the quantity, nature, and handling of incomplete
outcome data). We assessed methods used to deal with
incomplete data as having low risk of bias (< 10% of participants
did not complete the study or ≥ 10% with sensitivity analysis or
mixed model analysis); unclear risk of bias (used ’last or baseline
observation carried forward’ analysis, as progression in terms of
fatigue is not unexpected in advanced cancer patients with
missing outcome data); or high risk of bias (used ’completer’
analysis or post-intervention t-test)
• Selective reporting (checking for possible reporting bias).
We assessed studies as being at low risk of bias (all data fully
reported in the study); unclear risk of bias (data not fully
reported in the study, but study authors responded to data
requests); or high risk of bias (data not fully reported in the
study, and study authors did not respond to data requests).
• Size of the study (checking for possible biases confounded
by small size). We assessed studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); or high risk of bias (< 50
participants per treatment arm).
• Yates 2005 designed a quality rating scale to measure the
quality of RCTs for psychological interventions. On the basis of
recommendations provided by Yates and colleagues, we included
two additional items that can be used to assess the quality of the
control condition and efforts made to ensure that as many
features as possible have been controlled for (adequate, partial,
inadequate); and equality of treatment expectations (adequate,
inadequate). Furthermore, when reported, we took into account
the allegiance of the therapist and/or researcher to a particular
psychosocial intervention (see Characteristics of included studies
table) (Berman 1985; Dragioti 2015; Wampold 2001).
Measures of treatment effect
We evaluated fatigue outcomes at both post-intervention and fol-
low-up assessments using RevMan (RevMan 2014).We calculated
mean differences (MDs) and 95% confidence intervals (CIs) for
continuous data. If not reported, we planned to calculate stan-
dard deviations using methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
standardised mean differences of assessment tools measuring fa-
tigue in different ways to combine results across tools and used
mean differences otherwise. We planned to calculate risk ratios
(RRs) and 95% CIs when dichotomous data were reported (i.e.
for studies measuring fatigue as present or absent). We planned
to report the proportions of participants experiencing any adverse
events of psychosocial interventions, and to combine studies using
RRs (and 95% CIs).
Unit of analysis issues
One study included more than two intervention arms (Johansson
2008). We decided that we would combine into one intervention
group the three arms that provided relevant interventions for the
aim of this review. We planned to report intra-cluster correlations
and to make adjustments when necessary for any identified ran-
domised cluster trials.
Dealing with missing data
We analysed data for all participants in the group to which they
were randomised, regardless of whether they received the allocated
treatment.We did not exclude trials on the basis ofmissing data. In
the Discussion section, we address the potential impact of missing
data on review findings.
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Assessment of heterogeneity
We assessed clinical diversity by documenting participant charac-
teristics represented in each study, with focus on factors such as
age, gender, study eligibility criteria, cancer diagnosis, and can-
cer treatment. Furthermore, we documented heterogeneity in psy-
chosocial interventions, such as duration, delivery, profession of
care providers, and nature of the control condition. In addition,
we assessed diversity among ways of measuring fatigue and timing
fatigue assessment.
Assessment of reporting biases
We used a funnel plot to assess the possibility that publication bias
affected this review as a whole.
Data synthesis
Two review authors (HP, MP) independently assessed heterogene-
ity through visual inspection of the forest plot and on the basis
of quantitative results of both the X2 and the I2 statistic. We per-
formed meta-analysis for clinically homogeneous studies accord-
ing to the inverse-variance method for continuous outcomes. We
planned to use a fixed-effect model, but given that participant
populations were highly variable in cancer diagnosis and treat-
ment (as were the interventions provided), we employed random-
effects models. We expressed results as standardised mean differ-
ences (SMDs) or mean differences (MDs) for continuous out-
comes. For dichotomous outcomes, we would have expressed re-
sults as risk ratios (RR) using the Mantel-Haenszel method. We
used Review Manager software for analysis (RevMan 2014) and
have presented a narrative synthesis of studies for which required
data were unavailable for meta-analysis.
Quality of the evidence
Two review authors (HP, MP) independently rated the quality of
each outcome. We applied the GRADE (Grades of Recommenda-
tion, Assessment, Development, and Evaluation) system to rank
the quality of evidence using the GRADEprofiler Guideline De-
velopment Tool software (GRADEpro 2015) and guidelines pro-
vided in Chapter 12.2 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
The GRADE approach is based on five considerations (study lim-
itations, consistency of effect, imprecision, indirectness, and pub-
lication bias) for assessment of the quality of evidence for each
outcome. The GRADE system uses the following criteria to assign
a grade to the quality of evidence.
• High: We are very confident that the true effect lies close to
the estimate of effect.
• Moderate: We are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect but may be substantially different.
• Low: Our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of
effect.
• Very low: We have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We decreased the grade rating by one (- 1) or two (- 2) if we
identified:
• serious (-1) or very serious (-2) limitations to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1); or
• high probability of reporting bias (-1).
’Summary of findings’ table
We included a ’Summary of findings’ table to present the main
findings in a transparent and simple tabular format. In particular,
we included key information concerning the quality of evidence,
the magnitude of effect of interventions examined, and the sum of
available data on outcomes of fatigue, physical functioning, social
functioning, role functioning, emotional functioning, cognitive
functioning, and adverse events of psychosocial interventions.
Subgroup analysis and investigation of heterogeneity
When sufficient data were available, we planned to undertake sub-
group analysis for the primary outcome based on aspects of the
intervention that may influence its effectiveness: duration (short
vs intermediate-long), intervention delivery (group vs individual,
psychologist vs other profession), intervention type (monodisci-
plinary vs multi-disciplinary), and aim of the intervention (aimed
at decreasing fatigue vs other).We did not perform subgroup anal-
ysis for the intervention deliverer (psychologist vs other profes-
sional), as insufficient data were available. In addition, we planned
to perform subgroup analysis for the type of assessment tool (con-
tinuous vs dichotomous) and for studies in which some level of
fatigue was an eligibility criterion for patient participation versus
those in which it was not. Owing to insufficient available data, we
were unable to perform these subgroup analyses. Given the few
identified studies at low overall risk of bias (i.e. estimated low risk
of bias in all domains of the ‘Risk of bias’ assessment), we did not
use subgroup analysis based on overall risk of bias. We performed
post hoc subgroup analyses on the basis of additional sessions pro-
vided between post intervention and first and second follow-up
assessments of fatigue (no additional sessions vs booster sessions).
Sensitivity analysis
We performed post hoc sensitivity analyses based on the number
of participants per treatment arm at post-intervention and follow-
up assessments, while excluding studies with fewer than 10 par-
ticipants per treatment arm.
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R E S U L T S
Description of studies
We have summarised key characteristics of the included studies
below and in the Characteristics of included studies tables. We
have listed excluded studies with potential relevance to this review
along with reasons for their exclusion in the Characteristics of
excluded studies table.
Results of the search
Our search identified 1909 unique citations after removal of du-
plicates through database searching. We identified an additional
seven citations through conference abstracts or other references.
After initial screening of the 1916 titles and abstracts for relevance
to the review, we retained 171 citations. We were unable to retrieve
full texts for four citations and excluded 132 additional citations
when review of the full text and in some cases correspondence with
original study investigators revealed that they did not meet review
eligibility criteria. We excluded 21 studies (23 reports) with rea-
sons. Therefore, we included in the review 14 studies (16 reports)
that met the inclusion criteria. For further details of our screening
process, see the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Design
All 14 included studies were RCTs. In 13 studies, the unit of ran-
domisation was the individual participant (Armes 2007; Barsevick
2004; Barsevick 2010; Bordeleau 2003; Bruera 2013; Chan 2011;
Classen 2001; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel
1981; Steel 2016; Walker 2014). In one study, the unit of ran-
domisation was a group of 20 participants, 10 of whom were ran-
domised to each condition (Edelman 1999).
Setting
Six studies were conducted in the United States of America
(Barsevick 2004; Barsevick 2010; Bruera 2013; Classen 2001;
Spiegel 1981; Steel 2016), three in the UK (Armes 2007; Sharpe
2014; Walker 2014), two in Canada (Bordeleau 2003; Savard
2006), one inAustralia (Edelman 1999), one inHongKong (Chan
2011), and one in Sweden (Johansson 2008). Primary settings
were university-affiliated hospitals in five studies (Bordeleau 2003;
Classen 2001; Spiegel 1981; Johansson 2008; Savard 2006), can-
cer centres in seven studies (Armes 2007; Bruera 2013; Barsevick
2004; Barsevick 2010; Sharpe 2014; Steel 2016; Walker 2014),
and a public hospital in two studies (Chan 2011; Edelman 1999).
Cancer diagnosis
In this review, we were interested in the effects of psychosocial
interventions on participants with a diagnosis of incurable cancer.
In six studies, all participants received a diagnosis of incurable can-
cer (Bruera 2013; Bordeleau 2003; Classen 2001; Edelman 1999;
Savard 2006; Spiegel 1981). Five of these studies included par-
ticipants with metastatic breast cancer (Bordeleau 2003; Classen
2001; Edelman 1999; Savard 2006; Spiegel 1981); the other study
included patients with any diagnosis of advanced cancer (Bruera
2013). The eight remaining studies included a mixed sample of
participants with a diagnosis of incurable and potentially curable
cancer (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011;
Johansson 2008; Sharpe 2014; Steel 2016; Walker 2014). The
original study investigators of those eight studies were able to pro-
vide data for their subset of participants with incurable cancer;
thus we included them in the review.
Cancer treatment
In this review, we focused on effects of psychosocial interven-
tions for participants receiving cancer treatment. In five studies,
all participants were receiving cancer treatment during the in-
tervention (Armes 2007; Barsevick 2004; Barsevick 2010; Chan
2011; Classen 2001). In seven studies, although not all partici-
pants were receiving cancer treatment (Bordeleau 2003; Johansson
2008; Savard 2006; Sharpe2014; Spiegel 1981; Steel 2016;Walker
2014), the original study investigators were able to extract data
for their subset of participants receiving cancer treatment; thus we
included these studies in the review. In the remaining two stud-
ies, it is unclear or unknown whether all participants were receiv-
ing cancer treatment (Bruera 2013; Edelman 1999). We sought
clarification from the original study investigators. Bruera 2013
confirmed that all participants were receiving cancer treatment.
Edelman1999 did not collect data onwhowas receiving treatment
at the time of study participation, but we believe it is likely that
participants were receiving at least some form of cancer treatment
during the intervention, given the study population of participants
with metastatic breast cancer. Therefore, we included both studies
in the review.
Participants
Total sample sizes for the included studies ranged from 45 (Savard
2006) to 500 randomised participants (Sharpe 2014). However,
as noted before, not all participants were given a diagnosis of in-
curable cancer and/or were receiving cancer treatment. As a re-
sult, sample sizes for the subset of participants of interest to this
review were much smaller, ranging from 15 (Walker 2014) to 110
evaluable participants (Chan 2011) at post-intervention assess-
ment. Information on age and gender distribution was available
for the total samples of included studies but not for the subset of
interest to our review. Participants’ mean age for the total sample
ranged from 50 years (Edelman 1999) to 64 years (Walker 2014).
Chan 2011 reported no information on age distribution but pro-
vided these data upon request. Nine studies included both men
and women (Armes 2007; Barsevick 2004; Barsevick 2010; Bruera
2013; Chan 2011; Johansson 2008; Sharpe 2014; Steel 2016;
Walker 2014), and the proportion of males in the total sample
ranged from 10% (Sharpe 2014) to 83% (Chan 2011). Four stud-
ies targeted only women (Bordeleau 2003; Classen 2001; Savard
2006; Spiegel 1981). Edelman 1999 provided no information on
the gender distribution of participants. We believe it is likely that
only women were included, given the study population of partici-
pants with metastatic breast cancer. Finally, it is important to note
that Sharpe 2014 and Walker 2014 recruited only patients with a
diagnosis of major depression comorbid with cancer.
Content of the intervention
We have provided a detailed description of the interventions de-
livered in the Characteristics of included studies table. Interven-
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tions from 10 studies fell into one of three categories: cognitive-
behavioural therapies (n = 5; Armes 2007; Savard 2006; Edelman
1999; Johansson 2008; Steel 2016), supportive-expressive group
therapies (n = 3; Bordeleau 2003; Classen 2001; Spiegel 1981),
and energy conservation approaches combined with activity man-
agement or sleep modification techniques (n = 2; Barsevick 2004;
Barsevick 2010). Four interventions did not fall within these
categories. In Bruera 2013, the intervention included psychoso-
cial support and education combined with methylphenidate or
placebo. The intervention in Sharpe 2014 and Walker 2014 in-
cluded antidepressant medication provided in combination with
problem-solving therapy and behavioural activation. Chan 2011
examined the effects of a psychoeducational intervention consist-
ing of education and relaxation. It was unclear whether the inter-
vention protocol used in this study included some kind of per-
sonal feedback. We sought clarification from the original study
investigators, who confirmed that participants received personal
feedback.
Nature of the intervention
The purpose of the interventions varied. Six studies investigated
interventions specifically aimed at addressing fatigue (Armes 2007;
Barsevick 2004; Barsevick 2010; Bruera 2013; Chan 2011; Steel
2016). In addition to fatigue, Steel 2016 aimed to reduce depres-
sion and pain with the intervention provided. The intervention of
Chan 2011 aimed to reduce anxiety and breathlessness in addition
to fatigue. Two of the six studies required some level of fatigue
as an eligibility criterion for patient participation (Armes 2007;
Bruera 2013). In the remaining eight studies, the intervention was
aimed at mood disturbances and/or psychological benefit (Classen
2001; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981;
Walker 2014), quality of life (Bordeleau 2003), or survival benefit
(Edelman 1999).
Duration of the intervention
The total intervention duration varied between studies and ranged
from short (two to three weeks) in four studies (Bruera 2013;
Barsevick 2004; Barsevick 2010; Chan 2011) to long (12 months)
in three studies (Bordeleau 2003; Classen 2001; Spiegel 1981).
In the remaining seven studies, the intervention was given over a
period of two to eightmonths (classified as having an intermediate
duration) (Armes 2007; Edelman 1999; Johansson 2008; Savard
2006; Sharpe 2014; Steel 2016; Walker 2014). Steel 2016 did not
clearly state the total intervention duration, but it is likely that the
intervention was given over a period of six months, after which
the post-intervention assessment took place. In four studies, inter-
ventions consisted of an initial more intense intervention delivery
during the first two (Edelman 1999; Savard 2006) or four months
(Sharpe 2014; Walker 2014), followed by additional sessions (if
needed) for a period ranging from nine weeks (Savard 2006) to
eight months (Sharpe 2014).
Providers
In four studies, nurses delivered the intervention (Barsevick 2004;
Barsevick 2010; Bruera 2013; Chan 2011), and a combination of
therapists (i.e. two or more psychologists, psychiatrists, counsel-
lors, and/or social workers) delivered the intervention in five stud-
ies (Bordeleau 2003; Classen 2001; Edelman 1999; Spiegel 1981;
Savard 2006). In one study, psychologists, physiotherapists, and
nurses delivered the interventions (Johansson 2008). In two stud-
ies, non-clinicians (i.e. a research fellow (Armes 2007) or master’s
level/PhD therapists (Steel 2016)) did so. Finally, a team consist-
ing of a nurse, a psychiatrist, and the participant’s primary care
physician delivered the interventions in Sharpe 2014 and Walker
2014.
Delivery of the intervention
Researchers delivered psychosocial interventions using different
approaches. Six studies delivered interventions individually, either
face-to-face (Armes 2007; Chan 2011; Savard 2006) or by tele-
phone (Barsevick 2004; Barsevick 2010; Bruera 2013). Four stud-
ies used blended methods for intervention delivery, consisting of
individual face-to-face and telephone contacts (Johansson 2008;
Sharpe 2014; Steel 2016;Walker 2014). In addition to these deliv-
ery channels, Johansson 2008 used face-to-face group-based inter-
ventions, and Steel 2016 used aWeb-based platform. Four studies
delivered interventions in groups (Bordeleau 2003; Classen 2001;
Edelman 1999; Spiegel 1981).
Training and supervision
Ten studies (Armes 2007; Barsevick 2004; Barsevick 2010;
Bordeleau 2003; Bruera 2013; Chan 2011; Sharpe 2014; Spiegel
1981; Steel 2016; Walker 2014) reported that providers of the
intervention were trained. The remaining four studies did not re-
port whether providers were trained before delivering the inter-
vention (Classen 2001; Edelman 1999; Johansson 2008; Savard
2006). Eleven studies reported supervision of intervention de-
livery (Armes 2007; Barsevick 2004; Barsevick 2010; Bordeleau
2003; Bruera 2013; Johansson 2008; Savard 2006; Sharpe 2014;
Spiegel 1981; Steel 2016; Walker 2014). Three studies did not
report whether intervention delivery was supervised (Chan 2011;
Classen 2001; Edelman 1999).
Control condition
Nine studies compared the effects of a psychosocial intervention
versus usual care. In eight of these studies, usual care consisted of no
intervention (Armes 2007; Chan 2011; Edelman 1999; Johansson
2008; Sharpe 2014; Spiegel 1981; Steel 2016; Walker 2014); the
other study assigned participants to a wait list condition (Savard
2006). Three studies compared intervention effects versus an at-
tentional control (Barsevick 2004; Barsevick 2010; Bruera 2013).
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Classen 2001 provided participants in control conditions with a
self-directed educational intervention but also provided the edu-
cational materials to participants randomised to the intervention
condition. Bordeleau 2003 provided all participants with educa-




All 14 included studies reported fatigue as a primary, secondary,
or tertiary outcome. Ten studies used one instrument to mea-
sure fatigue (Bordeleau 2003; Chan 2011; Classen 2001; Edelman
1999; Johansson 2008; Savard 2006; Sharpe 2014; Spiegel 1981;
Steel 2016;Walker 2014). The remaining four studies used two or
more instruments (Armes 2007; Barsevick 2004; Barsevick 2010;
Bruera 2013). Five of the 14 studies used the fatigue subscale of the
Profiles of Mood States (POMS) (Barsevick 2004; Barsevick 2010;
Classen 2001; Edelman 1999; Spiegel 1981). Another five studies
used the fatigue scale of the EORTC QLQ-C30 (Armes 2007;
Bordeleau 2003; Johansson 2008; Sharpe 2014; Walker 2014).
The four remaining studies used other instruments to evaluate fa-
tigue: Functional Assessment of Chronic Illness Therapy (FACIT)
Fatigue Scale (Bruera 2013); Revised Piper Fatigue Scale, sub-
scale intensity (Chan 2011); Multidisciplinary Fatigue Inventory
(Savard 2006); and Functional Assessment of Cancer Treatment
(FACT) Fatigue (Steel 2016). The four studies evaluating fatigue
with more than one instrument used the following additional in-
struments: visual analogue scale (VAS) of global fatigue (Armes
2007); Schwartz Cancer Fatigue Scale (Barsevick 2004); General
Fatigue Scale (Barsevick 2004; Barsevick 2010); and the fatigue
subscale of the Edmonton Symptom Assessment Scale (ESAS)
(Bruera 2013). Except for the single-item VAS of global fatigue
used in the study of Armes 2007, all instruments comprise multi-
ple items designed to measure fatigue.
Physical, social, role, emotional, and cognitive functioning
Many studies used several measures of function. Eight stud-
ies assessed physical functioning (Armes 2007; Barsevick 2010;
Bordeleau 2003; Chan 2011; Johansson 2008; Savard 2006;
Sharpe 2014; Walker 2014). Six of those eight studies used the
physical functioning scale of the EORTC QLQ-C30, and the
other two studies used the physical component of the Short-Form
Health Survey (SF-12 and SF-36). Four studies assessed social
and role functioning (Bordeleau 2003; Johansson 2008; Sharpe
2014; Walker 2014) using the scales of the EORTC QLQ-C30.
Three studies assessed emotional functioning using the scale of
the EORTCQLQ-C30 (Bordeleau 2003; Johansson 2008) or the
mental component of the SF-12 (Barsevick 2010). Two studies as-
sessed cognitive functioning using the scale of the EORTCQLQ-
C30 (Bordeleau 2003; Johansson 2008). Two studies used other
measures to evaluate functioning. Barsevick 2004 used total score
for the Functional Performance Inventory - a 65-item scale con-
sisting of six subscales, including body care, household mainte-
nance, physical exercise, recreation, spiritual activities, and social
activities. In addition to physical andmental component summary
scores of the SF-12, Barsevick 2010 applied interference items
from the adapted Brief Pain Inventory to symptoms rather than to
pain only (SXINT) and assessed Eastern Cooperative Oncology
Group Performance Status.
Adverse events
Only three studies assessed adverse events of the intervention and
reported the number of adverse events for the total sample (Bruera
2013; Sharpe2014;Walker 2014). Bruera 2013 recorded the num-
ber of grade ≥ 3 adverse events. Sharpe 2014 and Walker 2014
defined adverse events as death from any cause, admission to a
psychiatric ward, or attempted suicide. In addition, Chan 2011 re-
ported that the sole reason for drop-out of participants was death.
Post-intervention outcome assessments
As a result of variance in intervention duration, the time between
baseline and post-intervention outcome evaluation ranged from
two weeks in Bruera 2013, to eight weeks in Savard 2006, to 26
weeks in Steel 2016, to 12 months in Bordeleau 2003, Classen
2001, and Spiegel 1981. Two studies reported on the post-inter-
vention assessment but did not clearly describe the number of
weeks or months between pre-intervention and post-intervention
assessment (Barsevick 2004; Edelman 1999). Armes 2007 pro-
vided an intervention consisting of three sessions coinciding with
administration of chemotherapy but did not mention the total
length of chemotherapy in number of days or weeks. Researchers
assessed outcomes at the end of chemotherapy (T1), four weeks
after the end of chemotherapy (T2), and nine months after re-
cruitment to the study (T3). Although the original study investi-
gators identified T2 as the main outcome for the study, we used
T1, as this was the first post-intervention assessment. Barsevick
2010 performed post-intervention assessment at days 43 to 46 or
days 57 to 60, depending on the type of cancer treatment par-
ticipants received. Sharpe 2014 provided the intervention over a
four-month period, then continued the intervention for a further
eight months. The primary endpoint for this study was the 24-
week assessment. Walker 2014 examined the same type of inter-
vention as Sharpe 2014 in a group of participants with a poor
prognosis for cancer. Given this poor prognosis, the intervention
was continued for a further four months instead of eight months.
Walker 2014 averaged fatigue data over participants’ time in the
study (up to a maximum of 32 weeks) into a single fatigue score,
but averaged fatigue scores were not available for meta-analysis.
Therefore, we used fatigue data collected at 24-week assessment,
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in line with Sharpe 2014. Johansson 2008 randomised partici-
pants to one of four study arms and performed assessments at 3,
6, 12, and 24 months after randomisation. Researchers combined
participants from the three intervention arms in this study into a
single intervention group for the aim of this review. However, the
three interventions had different durations and start points after
randomisation. We selected the six-month assessment as the post-
intervention assessment for our meta-analysis.
Follow-up outcome assessments
Eight studies included one (Barsevick 2004) or two follow-up as-
sessments (Armes 2007; Chan 2011; Edelman 1999; Johansson
2008; Savard 2006; Sharpe 2014;Walker 2014). However, four of
these studies (Edelman 1999; Savard 2006; Sharpe 2014; Walker
2014) provided more than one additional session (if needed) dur-
ing the follow-up period. Therefore, we excluded these studies
from primary meta-analyses for follow-up effects and included
them in subgroup analyses. The four remaining studies (Armes
2007; Barsevick 2004; Chan 2011; Johansson 2008) had different
follow-up durations. First follow-up durations ranged from three
weeks (Chan 2011) to six months (Johansson 2008) after post-
intervention assessment. Second follow-up administration varied
between studies and ranged from nine weeks (Chan 2011) to 18
months (Johansson 2008) after post-intervention assessment.
Excluded studies
Of the 155 full texts excluded from our review, only 21 studies (23
reports) had potential relevance to our study aim. We have listed
details regarding these 21 excluded studies in the Characteristics
of excluded studies table.
Ongoing studies
We identified two studies that have not been completed (
Poort; Serfaty) and listed characteristics of these studies in the
Characteristics of ongoing studies table.
Risk of bias in included studies
We assessed risk of bias using the Cochrane ‘Risk of bias’ tool
(Figure 2; Figure 3) (Higgins 2011).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Eight studies adequately described the method used to generate
the random sequence, and so we judged them to be at low risk of
bias for this domain (Armes 2007; Classen 2001; Edelman 1999;
Johansson 2008; Savard 2006; Sharpe 2014; Steel 2016; Walker
2014). Five studies did not specify the method of randomisation
used (Barsevick 2004; Barsevick 2010; Bordeleau 2003; Bruera
2013; Spiegel 1981), and we judged them to be at unclear risk
of bias. In addition, Chan 2011 used a ‘lucky draw method’ but
provided no description; therefore, we judged this study as having
unclear risk of bias. We identified no studies at high risk of bias
for this domain.
Allocation concealment
Six studies fully described how allocation of the sequence was
concealed, and we judged them to be at low risk of bias for this
domain (Armes 2007; Bordeleau 2003; Johansson 2008; Sharpe
2014; Steel 2016; Walker 2014). Eight studies did not adequately
describe how allocation of the sequence was concealed, and we
judged them to be at unclear risk of bias (Barsevick 2004; Barsevick
2010; Bruera 2013; Chan 2011; Classen 2001; Edelman 1999;
Savard 2006; Spiegel 1981). We found no studies at high risk of
bias for this domain.
Blinding
Five studies explicitly stated that outcome assessors were masked
to allocation, and we judged them to be at low risk of bias for
this domain (Chan 2011; Savard 2006; Sharpe 2014; Steel 2016;
Walker 2014). Nine other studies did not mention blinding of
outcome assessors or researchers, and we judged them to be at
unclear risk of bias (Armes 2007; Barsevick 2004; Barsevick 2010;
Bordeleau 2003; Bruera 2013; Classen 2001; Edelman 1999;
Johansson 2008; Spiegel 1981). We identified no studies at high
risk of bias for this domain.
Incomplete outcome data
Eight studies had less than 10% or 10% or more missing data
in the original study sample but used adequate statistical analy-
sis; therefore, we judged these studies to be at low risk of bias
for this domain (Armes 2007; Barsevick 2004; Barsevick 2010;
Bordeleau 2003; Chan 2011; Sharpe 2014; Steel 2016; Walker
2014). Three studies had more than 10% missing data and in-
cluded only patients with at least one observation post randomi-
sation in the mixed model or slopes analysis, and we judged them
to be at unclear risk of bias (Classen 2001; Savard 2006; Spiegel
1981). The remaining three studies had 10% or more missing
data, and we judged them to be at high risk of bias on the basis of
their adopted method of analysis (Bruera 2013; Edelman 1999;
Johansson 2008). Of note, we based all judgements on original
study samples because information on attrition for the subset of
interest for this review was not available.
Selective reporting
Thirteen studies adequately reported fatigue outcomes for the
original study sample, and we judged them to be at low risk
of bias for this domain (Armes 2007; Barsevick 2004; Barsevick
2010; Bordeleau 2003; Bruera 2013; Chan 2011; Classen 2001;
Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014;
Spiegel 1981; Walker 2014). In Steel 2016, study authors per-
formed two separate analyses but presented data from one analy-
sis only (i.e. for the subgroup of participants reporting clinically
significant symptoms at baseline). However, the original study in-
vestigators provided data for the total group on request; thus, we
judged this study to be at unclear instead of high risk of bias. We
identified no studies at high risk of bias for this domain. Visual
inspection of the funnel plot did not suggest publication bias.
Other potential sources of bias
Size of study
We provided information on total sample size because we used
this information in a few analyses. On the basis of total sample
sizes, we found that four studies had fewer than 50 participants
per treatment arm, and we judged them to be at high risk of bias
for this domain (Armes 2007; Bruera 2013; Savard 2006; Spiegel
1981). Nine studies included between 50 and 199 participants per
treatment arm, and we judged them to be at unclear risk of bias
(Barsevick 2004; Barsevick 2010; Bordeleau 2003; Chan 2011;
Classen 2001; Edelman1999; Johansson 2008; Steel 2016;Walker
2014). We identified one study with more than 200 participants
per treatment arm, andwe judged this study to be at low risk of bias
(Sharpe 2014).However, sample sizes for the subset of participants
with incurable cancer included in the meta-analysis were much
smaller. In fact, eight studies included in the subset meta-analysis
would be judged to be at high risk of bias for this domain on the
basis of fewer than 50 participants per treatment arm at baseline
(Armes 2007; Barsevick 2004; Barsevick 2010; Edelman 1999;
Johansson 2008; Savard 2006; Sharpe 2014; Walker 2014). The
four remaining studies reported between 50 and 199 participants
per treatment arm and we judged them to be at unclear risk of
bias (Bordeleau 2003; Chan 2011; Classen 2001; Steel 2016).
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Quality of the control condition
We judged the quality of the control condition to be adequate in
three studies (Barsevick 2004; Barsevick 2010; Bruera 2013). In
Barsevick 2004 and Barsevick 2010, control conditions were pro-
vided to control for the amount of time and attention received by
intervention groups. In Bruera 2013, participants in the control
condition also received (non-therapeutic) phone calls. We judged
four studies to have partially controlled features of the control
group (Bordeleau 2003; Chan 2011; Classen 2001; Steel 2016).
We judged that efforts made to ensure that as many features as
possible had been controlled for in the control group were inad-
equate in seven studies (Armes 2007; Edelman 1999; Johansson
2008; Savard 2006; Sharpe 2014; Spiegel 1981; Walker 2014).
Equality of treatment expectations
We judged three studies to show adequate equality of treatment
expectations between intervention and control groups (Bruera
2013; Barsevick 2004; Barsevick 2010). These three studies com-
pared effects of the intervention versus an attentional control. We
judged the remaining 11 studies to have inadequate treatment
expectations (Armes 2007; Bordeleau 2003; Chan 2011; Classen
2001; Edelman1999; Johansson 2008; Savard 2006; Sharpe 2014;
Spiegel 1981; Steel 2016; Walker 2014).
Allegiance of the therapist
No studies reported allegiance of the therapist and/or researcher.
Two studies (Bordeleau 2003; Classen 2001) were conducted to
replicate the findings of previous research on effects of supportive-
expressive group therapy (SEGT). Thus, we assumed that investi-
gators had at least some allegiance to SEGT.
Effects of interventions
See: Summary of findings for the main comparison
See Summary of findings for the main comparison.
Review authors were interested in the effects of psychosocial in-
terventions versus usual care or control conditions (not psychoso-
cial interventions) in participants with incurable cancer receiving
cancer treatment with palliative intent. As mentioned earlier, sev-
eral studies had a mixed sample of participants with incurable and
potentially curable cancer and/or receiving and not receiving can-
cer treatment during the psychosocial intervention. The analyses
described in the following sections are subset meta-analyses, in-
cluding only those participants of interest for our review.
Twelve of the 14 included studies were able to provide fatigue
data for meta-analysis on the subset of interest for this review
involving 535 participants in total at post-intervention assess-
ment (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011;
Classen 2001; Edelman 1999; Johansson 2008; Savard 2006;
Sharpe 2014; Spiegel 1981; Steel 2016; Walker 2014). With re-
spect tomeasures of physical, social, role, emotional, and cognitive
functioning, we received data from two to seven studies, depend-
ing on the specific domain of functioning. Although Bordeleau
2003 could not provide fatigue data, these investigators were able
to provide data for all five domains of functioning.Data on adverse
events were not available for the subset of interest for our review,
but we have provided later in this section a narrative description
of adverse events in the total sample.
As we were pooling data from heterogeneous populations and in-
terventions, we used random-effects instead of fixed-effectmodels.
Overall, we judged the quality of evidence for psychosocial inter-
ventions to be very low. We downgraded the quality of evidence
by two levels for risk of bias and imprecision.
Fatigue
Subset meta-analysis did not suggest a post-intervention outcome
benefit for the psychosocial intervention group compared with the
control group on the fatigue outcome measured with different in-
struments (standardised mean difference (SMD) -0.25, 95% con-
fidence interval (CI) -0.50 to 0.00; P = 0.05; participants = 535,
studies = 12; I2 = 43%; Analysis 1.1; Figure 4). We found very
low-quality evidence to suggest benefit of psychosocial interven-
tions for the secondary outcome of fatigue at first follow-up (SMD
-0.66, 95% CI -1.00 to -0.32; P = 0.0001; participants = 147,
studies = 4; I2 = 0%; Analysis 1.2; Figure 5). Psychosocial inter-
ventions did not influence secondary fatigue outcomes at second
follow-up (SMD -0.41, 95% CI -1.12 to 0.30; P = 0.26; partici-
pants = 91, studies = 2; I2 = 29%; Analysis 1.3; Figure 6).
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Figure 4. Forest plot of comparison: 1 Fatigue, outcome: 1.1 Post intervention.
Figure 5. Forest plot of comparison: 1 Fatigue, outcome: 1.2 First follow-up.
Figure 6. Forest plot of comparison: 1 Fatigue, outcome: 1.3 Second follow-up.
Non meta-analysed data
Investigators of two included studies responded to our data re-
quest but were unable to provide separate fatigue outcome data for
meta-analysis. Bruera 2013 had a homogeneous sample of partici-
pants with incurable cancer receiving cancer treatment and found
no statistically significant differences in median improvement of
FACIT Fatigue scores (P = 0.27) or ESAS Fatigue scores (P = 0.14)
between intervention and control groups. Bordeleau 2003 had a
homogeneous sample of participants with incurable cancer, but
not all participants were receiving cancer treatment. This study
found significant across-time deterioration in EORTCQLQ-C30
Fatigue scores (P = 0.003) using a mixed model for repeated mea-
sures. However, this deterioration did not differ between study
arms; therefore, this study could not demonstrate a significant in-
tervention effect.
Physical functioning
We found very low-quality evidence to suggest a post-intervention
outcome benefit of psychosocial interventions for physical func-
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tioning measured with different instruments (SMD 0.32, 95%
CI 0.01 to 0.63; P = 0.04; participants = 307, studies = 7; I2 =
35%; Analysis 2.1). Psychosocial interventions were not associated
with statistically significant improvement in physical functioning
at first follow-up (SMD 0.37, 95% CI -0.20 to 0.94; P = 0.21;
participants = 122, studies = 2; I2 = 36%; Analysis 2.2).
Non meta-analysed data
Armes 2007 provided raw values instead of transformed scores for
physical functioning, and we could not use these for meta-anal-
ysis. This study had a mixed-stage sample of participants receiv-
ing cancer treatment for incurable and potentially curable cancer.
Study investigators used a random-slope/random-intercept mixed
model and reported significant improvement in physical function-
ing for the original study population (coefficient 10, 95% CI 2.5
to 17.5; P = .009). However, we cannot conclude whether this
improvement also applies to the small subset of participants with
incurable cancer.
Social functioning
We saw no effect of psychosocial interventions on post-interven-
tion social functioning measured on the scale of the EORTC
QLQ-C30 (mean difference (MD) 4.16, 95%CI -11.20 to 19.53;
P = 0.60; participants = 141, studies = 4; I2 = 55%; Analysis 3.1).
Role functioning
Psychosocial interventions did not influence post-intervention role
functioning as measured with the EORTC QLQ-C30 scale (MD
3.49, 95%CI -12.78 to 19.76; P =0.67; participants = 143, studies
= 4; I2 = 52%; Analysis 4.1).
Emotional functioning
Psychosocial interventions did not influence post-intervention
emotional functioning as measured with different instruments
(SMD -0.11, 95% CI -0.56 to 0.35; P = 0.65; participants = 115,
studies = 3; I2 = 23%; Analysis 5.1).
Cognitive functioning
Results showed no overall effect of psychosocial interventions
on post-intervention cognitive functioning measured with the
EORTC QLQ-C30 scale (MD -2.23, 95% CI -12.52 to 8.06, P
= 0.67; participants = 86, studies = 2; I2 = 23%; Analysis 6.1).
Adverse events
Data on adverse events were available only for the total samples of
three studies (Bruera 2013; Sharpe 2014; Walker 2014). Bruera
2013 had a homogeneous sample of participants with incurable
cancer receiving cancer treatment and reported that the number
of grade ≥ 3 adverse events was similar between methylphenidate
and placebo arms, which were combined with a nursing or con-
trol intervention. Sharpe 2014 had a mixed-stage sample of par-
ticipants with incurable and potentially curable cancer either re-
ceiving or not receiving cancer treatment. This study reported 34
cancer-related deaths (7%) during the trial (19 in the intervention
group and 15 in the usual care group), one admission to a psychi-
atric ward (intervention group), and one attempted suicide (in-
tervention group) for the total sample. Study investigators deter-
mined that none of these events was related to trial treatments or
procedures. Walker 2014 had amixed-stage sample of participants
with incurable and potentially curable cancer either receiving or
not receiving cancer treatment. This study reported 43 cancer-
related deaths (30%) during the trial for the total sample (21 in
the intervention group and 22 in the usual care group). No other
serious adverse events occurred.
Subgroup analyses
Intervention duration: short versus intermediate-long
Three studies (participants = 163) were classified as having short
intervention durations (two to three weeks; Barsevick 2004;
Barsevick 2010; Chan 2011). The remaining nine studies (par-
ticipants = 372) had intermediate (two to eight months) or long
(12 months) intervention durations (Armes 2007; Classen 2001;
Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014;
Spiegel 1981; Steel 2016;Walker 2014).Meta-analysis to examine
post-intervention results for these subgroups did not demonstrate
a subgroup difference (Chi2 = 0.21; P = 0.65; participants = 535,
studies = 12; I2 = 0%; Analysis 7.1).
Intervention delivery: individual versus group
Three studies (participants = 195) delivered interventions in
groups (Classen 2001; Edelman 1999; Spiegel 1981). Eight stud-
ies (participants = 312) had interventions delivered individu-
ally (Armes 2007; Barsevick 2004; Barsevick 2010; Chan 2011;
Savard 2006; Sharpe 2014; Steel 2016; Walker 2014). One
study (Johansson 2008) delivered interventions individually or in
groups; we did not include this study in the subgroup analysis.
We found no evidence supporting a subgroup difference (Chi2 =
0.14; P = 0.70; participants = 507, studies = 11; I2 = 0%; Analysis
7.2).
Intervention type: monodisciplinary versus multi-
disciplinary
Nine studies (participants = 452) had interventions delivered
by professionals from a single discipline (Armes 2007; Barsevick
2004; Barsevick 2010; Chan 2011; Classen 2001; Edelman 1999;
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Savard 2006; Spiegel 1981; Steel 2016). Three studies (partici-
pants = 83) had interventions delivered by professionals from two
or more disciplines (Johansson 2008; Sharpe 2014;Walker 2014).
We found no evidence supporting a subgroup difference (Chi2 =
0.20; P = 0.66; participants = 535, studies = 12; I2 = 0%; Analysis
7.3).
Intervention aim: fatigue specific versus other aim
Five studies (participants = 232) providing fatigue outcome data
for meta-analysis investigated the effects of a psychosocial inter-
vention aimed at fatigue (Armes 2007; Barsevick 2004; Barsevick
2010; Chan 2011; Steel 2016). The remaining seven studies (par-
ticipants = 303) had different intervention aims (Classen 2001;
Edelman 1999; Johansson 2008; Savard 2006; Sharpe 2014;
Spiegel 1981; Walker 2014). We found no evidence supporting a
subgroup difference (Chi2 = 1.08; P = 0.30; participants = 535,
studies = 12; I2 = 7.5%; Analysis 7.4).
Additional sessions: no additional sessions versus booster
sessions
Four studies (participants = 147) provided no additional sessions
between post-intervention and first follow-up assessments and
thus were included in the primary meta-analysis for fatigue at first
follow-up (Armes 2007; Barsevick 2004; Chan 2011; Johansson
2008; Analysis 1.2). Four additional studies provided booster ses-
sions between post-intervention and first follow-up assessments
(Edelman 1999; Savard 2006; Sharpe 2014; Walker 2014). Three
of these studies provided data for first follow-up (Edelman 1999;
Sharpe 2014; Walker 2014). We found no evidence supporting a
subgroup difference (Chi2 = 0.61; P = 0.44; participants = 270,
studies = 7; I2 = 0%; Analysis 7.5). Two studies (participants =
91) provided no additional sessions between post-intervention and
second follow-up assessments and were included in the primary
meta-analysis for fatigue at second follow-up (Armes 2007; Chan
2011; Analysis 1.3). Three studies provideddata for second follow-
up but included booster sessions (Edelman 1999; Sharpe 2014;
Walker 2014). We found no evidence supporting a subgroup dif-
ference (Chi2 = 0.18; P = 0.67; participants = 202, studies = 5; I2
= 0%; Analysis 7.6).
Sensitivity analysis
Three of the 12 studies with fatigue outcomes featured in the post-
interventionmeta-analysis included fewer than 10 participants per
treatment arm post intervention (Armes 2007; Johansson 2008;
Walker 2014). We performed a sensitivity analysis with data from
these three studies removed. This analysis did not suggest a post-
intervention outcome benefit for the psychosocial intervention
group compared with the control group (SMD -0.30, 95% CI
-0.59 to 0.00; P = 0.05; participants = 476, studies = 9; I2 = 56%;
Analysis 8.1). At first and second follow-up, only one included
study assigned at least 10 participants per treatment arm (Chan
2011). Sensitivity analyses demonstrated that study findings (par-
ticipants = 153) were consistent with results of the primary meta-
analysis at first follow-up (SMD -0.70, 95% CI -1.10 to -0.30;
P = 0.0005; Analysis 8.2) and at second follow-up (SMD -0.23,
95% CI -0.67 to 0.22; P = 0.32; Analysis 8.3).
D I S C U S S I O N
Summary of main results
This review identified 14 studies for inclusion, with a wide range
of patient samples and psychosocial interventions. Twelve of the
14 studies provided data on fatigue for our subset meta-analysis
involving 535 participants post intervention. We found a lack of
clear evidence to support or not support the use of psychosocial in-
terventions for reducing fatigue in patients with incurable cancer
during cancer treatment. Seven of the 14 studies provided data on
physical functioning involving 307 participants post intervention.
Psychosocial interventions may improve physical functioning post
intervention, may reduce fatigue at first follow-up, or may achieve
both. However, most subsets of data were too small to be reli-
able, and only a limited number of studies with a limited number
of participants contributed to follow-up findings. Four of the 14
studies provided data on social and role functioning, three studies
on emotional functioning, and two studies on cognitive function-
ing. We found no evidence to support or not support the use of
psychosocial interventions for improving these domains of func-
tioning post intervention. In addition, there was a broad range of
interventions and follow-up durations across studies with consid-
erable attrition between assessments. Data on adverse events were
sparse. Only three studies that included pharmacological inter-
ventions in addition to psychosocial interventions (Bruera 2013;
Sharpe 2014; Walker 2014) reported on adverse events and found
no difference in the number of adverse events between interven-
tion and control groups.
Overall completeness and applicability of
evidence
We searched widely for evidence using five databases with no re-
striction on language and used search terms to identify as wide a
range of psychosocial interventions as possible. We found some
important gaps in the evidence.
The main limitation of this review involves the relative lack of
data in this field. Six studies consisted of a homogenous sample of
patients with incurable cancer. The remaining eight studies com-
prised a mixed sample of potentially curable and incurable pa-
tients. As a result, interventions from these eight studies were not
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specifically tailored to patients with incurable cancer. Yet, tailor-
ing of psychosocial interventions could be important in achieving
intervention effects, especially given the major difference in prog-
nosis between patients with incurable cancer and patients with po-
tentially curable cancer. Although investigators from these mixed-
sample studies were able to provide data for the subset of incurable
cancer patients, the sample sizes of these subsets were quite small.
This is likely to result in lack of power to detect treatment effects
that may arise from the psychosocial interventions. In addition,
our meta-analysis including means instead of individual patient
data for subsets of the total randomised study population is lim-
ited in that we were unable to adjust for potential confounding
factors. For these reasons, results of meta-analyses must be inter-
preted with caution.
We identified a limited number of studies (six) investigating inter-
ventions specifically aimed at addressing fatigue. However, only
two of these six studies reported that the presence of some level of
fatigue was an entry criterion for trial participation. This may lead
to floor effects, restricting the potential range of fatigue scores and
resulting in less room for improvement. Furthermore, a specific
feature of data available from identified studies was the hetero-
geneity of intervention and follow-up durations. In addition, only
four of the 12 studies contributed to findings on follow-up effects.
Three additional studies provided data for follow-up assessments,
but interventions in these studies continued between post-inter-
vention and follow-up assessments. Therefore, we excluded these
three studies from the primary follow-up analysis and included
them in subgroup analyses that did not find a significant effect.
Among the four studies included in the primary analysis for fol-
low-up effects, we noted considerable attrition between post-inter-
vention and first follow-up assessments (attrition rate 18.5%). Al-
though specific information on reasons for attrition for the subset
of interest for this review was not available, the attrition is unlikely
to be random. In fact, attrition may be associated with deteriora-
tion of health or death of the participant. This has implications
for interpretation of follow-up findings; thus these results should
be interpreted with caution.
Overall, studies predominantly comprised female participants.
This limits our ability to generalise research findings to male pa-
tients. Also, among the six studies that consisted of a homogeneous
sample of patients with incurable cancer, only one study investi-
gated intervention effects for a population other than metastatic
breast cancer (Bruera 2013). Finally, in two studies (Sharpe 2014;
Walker 2014), the investigated population had received a diag-
nosis of major depressive disorder comorbid with cancer. Fatigue
outcomes in these participants may have been associated with this
depression, making it difficult to distinguish fatigue as a symptom
of depression from cancer-related fatigue.
Quality of the evidence
We evaluated the overall quality of evidence using GRADE (see
Summary of findings for the main comparison). We downgraded
the GRADE quality of evidence for all outcomes to very low be-
cause of unclear risk of selection bias and imprecision due to sparse
data. We have very little confidence in the effect estimate, and the
true effect is likely to be substantially different from the estimate
of effect.
Potential biases in the review process
We conducted this review in keeping with the principles of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).We performed electronic database searches andmanual fol-
low-ups to look for additional references to maximise recall. None
of the authors of this review was involved in any of the excluded
or included studies. Two review authors independently assessed all
studies for inclusion, so we are confident that we have attempted
to reduce bias in the review process. However, as with all system-
atic reviews and meta-analyses, subjective judgement is involved at
various stages in the review process - from identification of studies
to data extraction and analysis. As a result, although search strate-
gies, data extraction, and analyses were thorough, relevant studies
and data may be missing.
Agreements and disagreements with other
studies or reviews
In the Cochrane review Goedendorp 2009 (co-authored by review
authors GB, MFG, and SV), which did not include a meta-anal-
ysis, review authors found limited evidence showing the effective-
ness of psychosocial interventions during cancer treatment in re-
ducing fatigue. They made no distinction in effectiveness between
psychosocial interventions provided for patients receiving cancer
treatment with curative or palliative intent. In our meta-analysis,
we did not find clear evidence supporting the effectiveness of a
range of psychosocial interventions for fatigue outcomes among
the subset of incurable cancer patients. In addition, Goedendorp
2009 concluded that psychosocial interventions designed specif-
ically to alleviate fatigue during cancer treatment are promising.
Our meta-analysis found no indication that interventions specif-
ically aimed at reducing fatigue had greater potential than inter-
ventions with a different aim for patients with incurable cancer re-
ceiving cancer treatment with palliative intent. This review high-
lights the current lack of evidence for psychosocial interventions
aimed at reducing fatigue in patients with incurable cancer receiv-
ing treatment with palliative intent. The optimal approach to psy-
chosocial intervention for fatigued patients with incurable cancer
and the true extent of potential benefits and harms remain uncer-
tain.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found insufficient evidence showing the effectiveness
of psychosocial interventions used to treat fatigue in patients with
incurable cancer receiving treatment with palliative intent. There-
fore, specific implications for patients with incurable cancer, for




Further evidence is needed from high-quality trials with large sam-
ples that fully report methodological characteristics and potential
harms. We identified two ongoing studies that aim to enrol 240
participants (Serfaty) and 219 participants (Poort) with a diagno-
sis of incurable cancer. With large samples, both studies have the
potential to provide substantial assistance to those seeking answers
to the research question that is the topic of this review.
Population
Additional studies with a homogeneous study sample of patients
with incurable cancer are needed. Targeting patients most in
need (i.e. those reporting clinically significant levels of fatigue)
to eliminate potential floor effects has been recommended before
(Bower 2014) and would be a helpful approach in future stud-
ies. Also, future studies should expand the focus beyond patients
with metastatic breast cancer, as it is unknown whether findings
from this patient group can be generalised to patients with other
cancer diagnoses. Therefore, enriching the evidence with studies
that focus on patients diagnosed with other types of incurable can-
cer would be helpful. Moreover, future studies should include a
substantial proportion of male participants and should determine
whether gendermoderates treatment outcomes, asmost of the par-
ticipants in studies conducted thus far have been females. Finally,
given the difficulty of recruiting large enough samples in palliative
care trials, multi-centre studies are recommended, as studies with
larger patient samples may detect small but clinically relevant dif-
ferences. Alternatively, application of novel research designs (e.g.
replicated n-of-1 trials) might be worthwhile given the difficul-
ties involved in conducting randomised controlled trials (RCTs)
of patients receiving cancer treatment with palliative intent.
Intervention
Psychosocial interventions are part of a broader portfolio of avail-
able interventions for cancer-related fatigue, which includes in-
terventions focused on physical activity and pharmacological ap-
proaches. For future research aimed at psychosocial interventions,
we recommend that protocols for a trial, including a detailed de-
scription of the intervention and its components, should be pub-
lished or otherwise made publicly available. Also, tailoring the
content of interventions to patients with incurable cancer would
be helpful, given the substantial difference in prognosis between
patients with potentially curable and incurable cancer. This dif-
ference has implications for the psychosocial factors thought to
maintain fatigue and addressed by the interventions. Moreover,
we would recommend short interventions delivered over a period
of several weeks or months, with follow-up assessments following
shortly (within three to eight months) after intervention delivery.
This is recommended not only to prevent participant attrition
(which complicates interpretation of findings) as much as possi-
ble, but also to minimise the burden of participation.
Comparison
Given the current state of the evidence, we recommend that re-
searchers conducting future trials should compare psychosocial in-
terventions versus usual care or attentional controls.
Outcome
No consensus has been reached on which instruments should be
used to measure fatigue and it would be helpful to reduce the vari-
ance among outcome instruments used to measure reduction in
fatigue. Future studies should clearly assess benefits and potential
adverse events (e.g. increased psychological distress) of the inter-
vention.
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Armes 2007
Methods Design: RCT.
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Participants UK, Guys and St. Thomas’ Hospital NHS Trust and Bromley Hospitals NHS Trust
60 patients (aged 59.1 years, 60% female) receiving chemotherapy and reporting signif-
icant fatigue
Interventions Intervention group: brief, cancer-related fatigue-specific, behaviourally oriented inter-
vention consisting of cognitive, behavioural, and general components
Control group: standard care; cancer-related fatigue was not assessed routinely and advice
regarding its management was delivered in an ad hoc manner
Outcomes VAS Fatigue, EORTCQLQ-C30Fatigue, andEORTCQLQ-C30Physical functioning.
Adverse events were not described
Notes Funding: Cancer Research UK Nursing Research Training Fellowship (CP1052/0101
and C1428/A180)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Originally, minimisation as the method of
treatment allocation. After the first 10 pa-
tients, simple random, permuted, block
randomisation implemented
Allocation concealment (selection bias) Low risk Statistician (unconnected to the study)
generated the randomisation, provided a
central telephone service for participant al-
location, and kept a copy of the randomi-
sation codes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Questionnaires posted or given to patients
in the chemotherapy clinic by first study
author. Insufficient information to permit
judgement of low or high risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 10% missing data, but data
analysed using t tests and random-slope/
random-intercept mixed models using a
generalised linear latent and mixed model
Selective reporting (reporting bias) Low risk All data fully reported in the study.
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Armes 2007 (Continued)
Size of the study High risk Fewer than 50 participants randomised per
treatment arm at baseline
Barsevick 2004
Methods Design: RCT.
Duration of study participation: depended on type of cancer treatment
Participants USA, University of Utah Health Science Center and Fox Chase Cancer Center
396 individuals (aged 56.3 years, 85% female) beginning chemotherapy, radiotherapy,
or concurrent therapy for breast, lung, colorectal, advanced prostate, gynaecological, or
testicular cancer or lymphoma
Interventions Energy Conservation and Activity Management (ECAM): information provided to aid
formation of an accurate representation of the symptom of fatigue, guide the formulation
and implementation of a plan for energy conservation, and appraise the effectiveness of
symptom-management efforts
Control group: information on nutrition and a healthy diet. No therapeutic nutritional
information or information on symptom management
Outcomes POMS Fatigue, Schwartz Cancer Fatigue Scale, General Fatigue Scale, and Functional
Performance Inventory. Adverse events were not described
Notes Funding: National Institute of Nursing Research (R01NR04573)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on the method of ran-
domisation was provided.
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
was provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding of outcome
assessors was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than10%missingdata for at least one
data point on at least one fatigue measure,
but use of SAS mixed procedure restricted
maximum likelihood method
Selective reporting (reporting bias) Low risk All data fully reported in the study.
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Barsevick 2004 (Continued)
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Barsevick 2010
Methods Design: RCT.
Duration of study participation: 43-46 days and 57-60 days, depending on length of the
chemotherapy cycle
Participants USA, Fox Chase Cancer Center.
292 patients (aged 53.9 years, 82% female) beginning a new chemotherapy regimen
for breast, lung, colorectal, prostate, gynaecological, bladder, or testicular cancer, or
lymphoma
Interventions Energy and Sleep Enhancement (EASE): information about the symptom’s identity,
cause, and pattern needed to form a mental image of the symptom and to identify and
implement self-care strategies to manage the symptom. Evaluation of the effectiveness
of strategies and adjustment of coping methods or symptom representation
Control intervention: information about nutrition and a healthy diet. Therapeutic nu-
tritional information or information on symptom management not included
Outcomes POMS Fatigue, General Fatigue Scale, and SF-12 Physical and Mental component
summary score. Adverse events not described
Notes Funding: National Institute of Nursing Research (R01NR04573)
Follow-up study of Barsevick 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on the method of ran-
domisation provided.
Allocation concealment (selection bias) Unclear risk Random assignments generated by statisti-
cian and placed in sealed envelopes, num-
bered and selected sequentially for each
stratification group. Unclear whether en-
velopes were opaque
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding of outcome
assessors provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 10% missing data and data were
analysed using SAS mixed procedure (i.e.
restricted maximum likelihood method)
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Barsevick 2010 (Continued)
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Bordeleau 2003
Methods Study design: RCT.
Duration of study participation: 12 months.
Participants Canada, Samual Lunenfeld Research Institute, Mount Sinai Hospital, University of
Toronto, and 6 other (regional) cancer centres
237 women with metastatic breast cancer.
Interventions Supportive-Expressive Group Therapy (SEGT): weekly 90-minute therapist-led support
group adhering to principles of supportive-expressive therapy. Intended to foster support
among group members while encouraging expression of emotions about cancer and its
effects on lives. Relaxation exercise at the end of each seminar
Control group: no participation in a support group. Every 6 months, all women received
educational materials about breast cancer and its treatment, relaxation, and nutrition. All
study participants could receive any medical or psychosocial treatment deemed necessary
Outcomes EORTCQLQ-C30 Fatigue, POMS Fatigue, EORTCQLQ-C30 Physical, Social, Role,
Emotional, and Cognitive functioning. Adverse events not described
Notes Funding: Medical Research Council of Canada and Canadian Breast Cancer Research
Initiative
Summary data for functional scales of the EORTC-QLQ-C30 were provided, but fatigue
data from the EORTC-QLQ-C30 or the POMS could not be provided (reason: “It
would take too much time to retrieve the data”)
Allegiance effect: This trial was designed to replicate the findings of a previous study on
the effects of SEGT, thus therapists and/or researchers probably had some allegiance to
SEGT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on the method of ran-
domisation provided.
Allocation concealment (selection bias) Low risk Randomisation performed centrally, strat-
ified for study centre and for the presence
of visceral metastases
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Questionnaires given to participants by the
research assistant during baseline assess-
ment, and mailed out 4, 8, and 12 months
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Bordeleau 2003 (Continued)
after randomisation. No information on
blinding of the research assistant provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 10% missing data, but data
analysed using SAS mixed model for re-
peated measures
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Bruera 2013
Methods Study design: RCT.
Duration of study participation: 2 weeks.
Participants USA, MD Anderson Cancer Center and Lundon B. Johnson General Hospital
190 patients with advanced cancer and reporting fatigue.
Interventions Nursing Telephone Intervention (NTI): 3 components: (1) symptom assessment, (2)
review of types and dosages of medications and adverse events, (3) psychosocial sup-
port and patient education. Research nurse asked open-ended questions regarding gen-
eral well-being of participant and family, listened empathetically, answered participant’s
questions, and provided supportive statements
Control group: non-therapeutic phone calls by a non-professional who assessed symp-
toms and asked about medications. No psychosocial support or education provided. If
participants raised concerns, they were directed to discuss them with their physician
Outcomes FACIT fatigue and ESAS Fatigue. Adverse events were documented
Notes Funding: National Institute of Health-National Institute of Nursing and ACS Research
Scholar Grant for Independent Investigators
Not eligible for meta-analysis. Summary data were requested but not could not be
provided (reason: “No staff support to deal with the request”)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported only that participants were ran-
domly assigned to receive 1 of 4 treatments
but not how randomisation was performed
Allocation concealment (selection bias) Unclear risk Not stated.
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Bruera 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported that all members of the research
teamwere blinded to treatment assignment
(methylphenidate or placebo), but reported
no information on blinding of outcome as-
sessors for the nursing or control telephone
intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk More than10%missingdata, not described
what was done with missing data, proba-
bly used complete-case analysis (only data
from evaluable patients). Median differ-
ences between intervention and control
groups analysed using Wilcoxon two-sam-
ple tests
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per
treatment arm at baseline
Chan 2011
Methods Study design: RCT.
Duration of study participation: 3 months.
Participants Tuen Mun Hospital, Hong Kong.
140 patients with advanced lung cancer.
Interventions Psychoeducational intervention (PEI): PEI alters patients’ perceptions and sensations
of symptoms through stress reduction; clarification of misconceptions; and adoption of
adaptive behaviours. A 40-minute educational package plus coaching of PMR delivered
to patients within 1 week before the beginning of the course of radiotherapy, and rein-
forced 3 weeks after radiotherapy is commenced
Usual care: mandatory individual briefing on the radiotherapy procedure and brief dis-
cussion of side effects by therapy radiographer
Outcomes Revised Piper Fatigue Scale Intensity subscale and SF-36 Physical functioning. Adverse
events not described
Notes Funding: Hong Kong Health Service Research Fund.
Personal feedback intended in the intervention protocol, as confirmed by the original
study investigator
Risk of bias
Bias Authors’ judgement Support for judgement
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Chan 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk No explanation on themethod of randomi-
sation (lucky draw method) provided
Allocation concealment (selection bias) Unclear risk Not reported how randomisation was per-
formed.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data were collected by a research assistant
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 10% missing data post interven-
tion. However, missing data imputed by
a carry-forward method although missing
data were not random but were related to
outcomes that can lead to attrition bias
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Classen 2001
Methods Study design: RCT.
Duration of study participation: 12 months.
Participants USA, Stanford University Medical Center.
125 women with metastatic breast cancer.
Interventions Supportive-Expressive Group Therapy (SEGT): Participants were encouraged to con-
front their problems, strengthen their relationships, and find enhanced meaning in their
lives in a supportive environment. Neither coping strategies nor psychoeducation taught
in a didactic manner. Self-hypnosis exercise at end of each session
Control group: self-directed educational intervention. Educational materials also offered
to women in the treatment condition
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: National Institute of Mental Health, National Cancer Institute, John D. and
Catherine T MacArthur Foundation, and the Fetzer Institute
Allegiance effect: This trial was designed to replicate the findings of a previous study on
the effects of SEGT, thus therapists and/or researchers probably had some allegiance to
SEGT
Risk of bias
Bias Authors’ judgement Support for judgement
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Classen 2001 (Continued)
Random sequence generation (selection
bias)
Low risk Adaptive randomisationbiased coin-design
method.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk For the first 2 years of the study, baseline
and post-baseline assessments completed
on a computer. No information on blind-
ing of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More than 10% missing data. Slopes anal-
ysis used, but only participants who pro-
vided at least one follow-up point included
in the analysis
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Edelman 1999
Methods Design: RCT.
Duration of study participation: 12 months.
Participants Australia, Royal North Shore Hospital.
124 women with metastatic breast cancer aged between 30 and 65 years
Interventions Cognitive-Behavioural Therapy (CBT): cognitive and behavioural techniques, expres-
sion of feelings, and building of group support. Manual, handouts, and homework pro-
vided. Emphasis on gaining greater sense of control through problem solving and goal
setting. Participants were instructed on effective communication strategies and were en-
couraged to communicate assertively with friends, family members, and medical staff
Control group: No-therapy control group condition. Patients were informed about other
community support groups that they could attend
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: not specified.
Risk of bias
Bias Authors’ judgement Support for judgement
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Edelman 1999 (Continued)
Random sequence generation (selection
bias)
Low risk For every 20 participants, a block randomi-
sation procedure took place, with 10 ran-
domised to each treatment condition
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding of outcome
assessors provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 10%missing data and data anal-
ysed using independent samples t-tests.
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Johansson 2008
Methods Design: RCT.
Duration of study participation: 24 months.
Participants Sweden, Uppsala University Hospital.
481 consecutive patients with newly diagnosed prostate, gastrointestinal, or breast cancer.
Women with a mammography finding requiring surgery could also be included
Interventions Intervention group: Individual support included individual psychological support, in-
tensified primary health care, and nutritional support for some participants, and implied
extra contact with at least two or three different professionals, irrespective of participants’
need for support. All participants were contacted by a project psychologist. Current
problems identified jointly by participants and by the psychologist were the focus of the
intervention. Techniques used were derived from cognitive-behavioural therapy, includ-
ing relaxation techniques, identification and challenging of negative automatic thoughts,
and activity scheduling and daily planning. Group rehabilitation conducted by a psy-
chologist, physiotherapist, and oncology nurse. Sessions included cognitive-behavioural
techniques, light physical training, and relaxation. In 2 sessions, a physician presented
information about cancer and cancer treatment, and a dietician provided dietary advice.
All sessions offered opportunities to disclose and discuss concerns with group leaders
and members
Control group: Standard care did not include regular follow-ups by a dietician or medical
social worker. Participants could be referred to such services
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, Role, Emotional,
and Cognitive functioning. Adverse events not described
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Johansson 2008 (Continued)
Notes Funding: Swedish Cancer Society.
Three different intervention groups: individual support, group rehabilitation, and com-
bined individual support and group rehabilitation. We combined these three groups
into one to have sufficient sample size for the subset of patients with incurable cancer
receiving systemic treatment with palliative intent (combined intervention groups n =
26 vs standard care group n = 17)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised by an indepen-
dent oncological centre (computer-gener-
ated allocation schedule). Randomisation
stratified for diagnosis and stage
Allocation concealment (selection bias) Low risk Participants randomised by an indepen-
dent oncological centre (computer-gener-
ated allocation schedule)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Research nurse gave participants the base-
line questionnaire with a prepaid enve-
lope. At subsequent assessments, partici-
pants were contacted by one of the investi-
gators by phone. Investigator gave instruc-
tions and mailed the questionnaires, writ-
ten instructions, and a prepaid envelope to
participants. No information on whether
investigators were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 10%missing data and data anal-
ysed using one-way ANOVAwith repeated
measures
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Savard 2006
Methods Design: RCT.
Duration of study participation: 36 weeks.
Participants Canada, three cancer clinics: Hôpital St-Sacrement, L’Hôtel-Dieu de Québec, and
L’Hôtel-Dieu de Lévis
45 patients with metastatic breast cancer reporting depressive symptoms
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Savard 2006 (Continued)
Interventions Cognitive therapy: presentation of cognitive theory of emotions. Participants were en-
couraged to increase their level of daily activities and were trained to identify their nega-
tive thoughts, to use cognitive restructuring, and to redefine their life goals. Future high-
risk situations were identified, as were strategies to cope with them
Control group: Participants waited for a period corresponding to the duration of the
intervention (8 weeks) and were reassessed on study variables before receiving cognitive
therapy
Outcomes Multidisciplinary Fatigue Inventory and EORTC QLQ-C30 Physical functioning. Ad-
verse events not described
Notes Funding: Canadian Breast Cancer Research Initiative (010436) and Canadian Institutes
of Health Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prepared by principal investigator before
study initiation using a computer-gener-
ated random numbers table
Allocation concealment (selection bias) Unclear risk Group allocation was contained in indi-
vidually sealed envelopes. Unclear whether
envelopes were sequentially sealed and
opaque
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At the post-treatment evaluation, partic-
ipants met the independent evaluator to
complete self-report scales. Evaluator was
blind to study objectives and procedures
and to participants’ group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More than 10%missing data. Linearmixed
models used to analyse data, but only par-
ticipants with at least one observation post
randomisation included in the analysis
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per
treatment arm at baseline
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Sharpe 2014
Methods Design: RCT.
Duration of study participation: 48 weeks.
Participants Scotland, UK, three cancer centres.
500 adults with a diagnosis of cancer, good cancer prognosis (predicted survival of at
least 12 months), and major depression of at least four weeks’ duration
Interventions Depression care: intensive, manualised, collaborative care-based multi-component treat-
ment programme specifically designed to be integrated with the patient’s cancer treat-
ment. Nurses establish a therapeutic relationship with participants, provide information
about depression and its treatment, deliver brief evidence-based psychological interven-
tions (problem-solving therapy and behavioural activation), and monitor participants’
progress. Psychiatrists supervise treatment, advise primary care physicians about prescrib-
ing antidepressants, and provide direct consultations to patients who are not improving
Usual care: participant’s primary care physician and oncologist were informed about the
major depression diagnosis and were asked to treat their patients as they normally would.
Participants were encouraged to consult their primary care physician to obtain treatment
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, and Role func-
tioning. Adverse events defined as death from any cause, admission to a psychiatric ward,
or attempted suicide
Notes Funding: University of Edinburgh, NHS Lothian, Cancer Research UK (grant numbers
C5547/A7375), Chief Scientist Office of the Scottish Government, and Scottish Mental
Health Research Network funded by NHS Research Scotland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Database software algorithm allocated par-
ticipants in a 1:1 ratio using a combination
of stratification (by trial centre) and min-
imisation (by age, primary cancer, and sex)
Allocation concealment (selection bias) Low risk Secure Web-based randomisation database
implemented by a trials unit
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial statistician and staff who collected
outcomedatamasked to allocated interven-
tions; however, participants could not be
masked because of the nature of depression
care for people with cancer
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 10%missing data. Analysis of co-
variance used for data analysis. In addition,
sensitivity analysis using multiple imputa-
tion was performed
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Sharpe 2014 (Continued)
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Low risk More than 200 participants randomised
per treatment arm at baseline
Spiegel 1981
Methods Design: RCT.
Duration of study participation: 12 months.
Participants USA, Stanford University School of Medicine.
86 women with metastatic breast cancer.
Interventions Psychosocial Support Group (PSG): designed to be supportive, with a high degree of
cohesion and relatively little confrontation and here-and-now interpersonal exploration.
Interaction in the group often included a considerable amount of self-disclosure and
sharing of mutual fears and concerns
Control group: not described.
Outcomes POMS Fatigue. Adverse events not described.
Notes Funding: National Cancer Institute (N01-CN-55313 [DHEW]) and Veterans Admin-
istration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on method of randomisa-
tion provided.
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding of outcome
assessors provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More than 10% missing data. Slopes anal-
ysis used to analyse data, but only partic-
ipants who completed at least two assess-
ments included in the analysis
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study High risk Fewer than 50 participants randomised per
treatment arm at baseline
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Steel 2016
Methods Design: RCT.
Duration of study participation: six months.
Participants USA, University of Pittsburgh Medical Center’s Liver Cancer Center
261 patients (aged 61 years, 73% male) with hepatocellular carcinoma, cholangiocar-
cinoma, gallbladder carcinoma, neuroendocrine carcinoma, pancreatic carcinoma, or
other primary cancers that had metastasised to the liver (e.g. ovarian, breast, colorectal
cancer)
Interventions Web-based stepped collaborative care intervention: access to a psychoeducational web-
site and to a collaborative care co-ordinator with training and experience in cognitive-
behavioural therapy and psycho-oncology
Control group: usual care provided by themedical team. For ethical reasons, participants
who scored high on a depression or pain measure were contacted by a care co-ordinator,
who provided education about symptoms and referral options
Outcomes FACT Fatigue. Adverse events not described.
Notes Funding: National Cancer Institute (K07CA118576, R21CA127046, and
P30CA047904)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned via a block
randomisation design according to sex and
vascular invasion
Allocation concealment (selection bias) Low risk Allocation concealment achieved through
use of a random numbers table that as-
signed consecutive participants across the
group. A research assistant who was not
part of the study placed trial assignments in
opaque envelopes consecutively per group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All data collected by trained interviewers
using a structured computerised interview.
Interviewers were blinded to study arm as-
signment
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 10% missing data. Two sepa-
rate general linear mixed-models analyses
performed: first with all participants, then
with participants with clinically significant
symptoms at baseline
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Steel 2016 (Continued)
Selective reporting (reporting bias) Unclear risk Effects of the intervention reported only for
the subgroup of participants with clinically
relevant symptoms at baseline (n = 132)l
results for the entire sample not presented
but provided upon request
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Walker 2014
Methods Design: RCT.
Duration of study participation: 32 weeks.
Participants Scotland, UK, three cancer centers.
142 adults with primary lung cancer, predicted survival of at least three months, and
major depression for four weeks or longer
Interventions Depression care: multi-component, systematic, team-delivered treatment programme
based on the collaborative care model and integrated with lung cancer care. Nurses estab-
lish a therapeutic relationship with participants, provide information about depression
and its treatment, deliver brief evidence-based psychological interventions (problem-
solving therapy and behavioural activation), and monitor participants’ progress. Psychi-
atrists supervise treatment, advise primary care physicians about prescribing to ensure
rapid initiation and proactive adjustment of antidepressants, and provide direct consul-
tations to patients who are not progressing
Usual care: participant’s primary care physician and oncologist were informed of the
diagnosis of major depression and were asked to treat participant as they normally would.
Participant was encouraged to see primary care physician to obtain treatment
Outcomes EORTC QLQ-C30 Fatigue and EORTC QLQ-C30 Physical, Social, and Role func-
tioning. Adverse events defined as death from any cause, admission to a psychiatric ward,
or attempted suicide
Notes Funding: University of Edinburgh, NHS Lothian, Cancer Research UK (grant numbers
C5547/A7375 and C25786/ A10093), Chief Scientist Office of the Scottish Govern-
ment, and ScottishMental Health ResearchNetwork funded byNHS Research Scotland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Database software algorithm allocated par-
ticipants in a 1:1 ratio using a combina-
tion of stratification (by trial centre) and
minimisation (by age, sex, and lung cancer
type)
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Walker 2014 (Continued)
Allocation concealment (selection bias) Low risk Secure Web-based randomisation database
implemented by a trials unit
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial statistician and staff who collected
outcomedatamasked to allocated interven-
tions; however, participants could not be
masked because of the nature of depression
care for people with cancer
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 10% missing data. A summary
measure approach used in the analysis of
covariance, which copes with missing data
and sensitivity analyses using multiple im-
putations
Selective reporting (reporting bias) Low risk All data fully reported in the study.
Size of the study Unclear risk Between 50 and 199 participants ran-
domised per treatment arm at baseline
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adamsen 2009 Mixed-sample study. No incurable cancer participants were receiving active cancer treatment
Anderson 2015 Unable to determine whether intervention fulfilled our formulated criteria; no response received from
study investigators
Berglund 2007 Mixed-sample study. Study investigators were unable to retrieve the data
Bigatao 2016 Unable to determine whether intervention fulfilled our formulated criteria, and whether study sample also
included participants with incurable cancer
Brown 2006 Does not meet our formulated criteria for psychosocial intervention. Study investigators confirmed that
personal feedback was not intended
Cunningham 1989 Unknownwhether study sample also includes patientswith incurable cancer.Unable to retrieve professional
contact address of study investigators
De Moor 2001 Did not meet our formulated criteria for psychosocial intervention
De Raaf 2013 Did not meet our formulated criteria for psychosocial intervention. Study investigators confirmed that
personal feedback was not intended
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(Continued)
Decker 1992 Mixed-sample study. Unable to retrieve professional contact address of study investigators
Fernandez 2011 No randomised controlled trial (RCT); study investigators confirmed that all baseline measures were taken
after randomisation
Focan 2015 Unable to determine whether intervention fulfilled our eligibility criteria; no detailed intervention content
information was received from study investigators
Forester 1985 Unknown whether study sample also included patients with incurable cancer. Unable to retrieve profes-
sional contact address of study investigators
Gaston-Johansson 2000 Mixed-sample study; no response received from study investigators
Given 2002 Mixed-sample study; study investigators not willing to provide data. Entire study sample included < 80%
of patients with incurable cancer, thus excluded from the review
Godino 2006 Unknown whether study sample also included patients with incurable cancer; no response received from
study investigators
Oh 2010 Unknown whether study sample also included patients with incurable cancer; no response received from
study investigators
Ream 2006 Mixed-sample study, request for separate summary data sent to study investigators but no response received
Ream 2015 Unknown whether study sample also included patients with incurable cancer; no response received from
study investigators
Serfaty 2012 Unknownwhether study sample also includedpatientswith incurable cancer. Study investigators confirmed
not knowing whether incurable cancer patients were part of the sample
Strong 2008 Mixed-sample study; study investigators unable to provide data
Yorke 2015 Did not meet formulated criteria for receiving cancer treatment. Study investigators confirmed that none
of the participants were receiving cancer treatment with palliative intent during the intervention
Characteristics of ongoing studies [ordered by study ID]
Poort
Trial name or title TIRED study.
Methods Randomised controlled trial (RCT).
Participants Netherlands, Radboud University Medical Center with sites set up across the Netherlands
219 patients with a diagnosis of incurable cancer and reporting severe fatigue
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Poort (Continued)
Interventions Cognitive-behavioural therapy (CBT): 12-week CBT intervention designed to treat severe fatigue during
systemic cancer treatment with palliative intent for incurable cancer. CBT consists of 10 individual, clinic-
delivered sessions and will be delivered by trained psychologists
Control condition: usual care. Participants may be referred to psychological or exercise interventions by their
general practitioner or oncologist
Outcomes Checklist Individual Strength, EORTCQLQ-C30 Fatigue, Sickness Impact Profile, and EORTC-QLQ C30
Physical, Social, Role, Emotional, and Cognitive functioning
Starting date January 2013, recruitment ongoing.
Contact information Hanneke Poort, MSc, Department of Medical Psychology, Radboud University Medical Center, Nijmegen,
The Netherlands
Notes Funding: Dutch Cancer Society (KUN2011-5259).
This study is performed by five of the review authors (HP, MP, GB, SV, HK)
Serfaty
Trial name or title CanTalk study.
Methods Randomised controlled trial (RCT).
Participants UK, University College London with sites set up across England
240 patients with advanced, non-curative cancer and a clinical diagnosis of depression
Interventions Cognitive-behavioural therapy (CBT) in addition to treatment as usual (TAU): up to 12 sessions of individual
CBT delivered face-to-face or on the telephone over three months
TAU: All participants receive TAU from oncology teams and from their general practitioners (GPs). Specific
psychological support may be available for those who present with psychological needs at any time
Outcomes Beck Depression Inventory-II single item for fatigue.
Starting date July 2012, recruitment completed.
Contact information Dr Marc Serfaty, Division of Psychiatry, University College London, London, UK
Notes Funding: National Institute for Health Research (NIHR) Health Technology Assessment Programme
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D A T A A N D A N A L Y S E S
Comparison 1. Fatigue




participants Statistical method Effect size
1 Post intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
2 First follow-up 4 147 Std. Mean Difference (IV, Random, 95% CI) -0.66 [1.00, -0.32]
3 Second follow-up 2 91 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.12, 0.30]
Comparison 2. Physical functioning




participants Statistical method Effect size
1 Post intervention 7 307 Std. Mean Difference (IV, Random, 95% CI) 0.32 [0.01, 0.63]
2 First follow-up 2 122 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.20, 0.94]
Comparison 3. Social functioning




participants Statistical method Effect size
1 Post intervention 4 141 Mean Difference (IV, Random, 95% CI) 4.16 [-11.20, 19.53]
Comparison 4. Role functioning




participants Statistical method Effect size
1 Post intervention 4 143 Mean Difference (IV, Random, 95% CI) 3.49 [-12.78, 19.76]
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Comparison 5. Emotional functioning




participants Statistical method Effect size
1 Post intervention 3 115 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.56, 0.35]
Comparison 6. Cognitive functioning




participants Statistical method Effect size
1 Post intervention 2 86 Mean Difference (IV, Random, 95% CI) -2.23 [-12.52, 8.06]
Comparison 7. Subgroup analyses




participants Statistical method Effect size
1 Fatigue post intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
1.1 Short intervention
duration
3 163 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.72, 0.48]
1.2 Intermediate-long
intervention duration
9 372 Std. Mean Difference (IV, Random, 95% CI) -0.28 [-0.57, 0.02]
2 Fatigue post intervention 11 507 Std. Mean Difference (IV, Random, 95% CI) -0.27 [-0.53, -0.00]
2.1 Group intervention
delivery
3 195 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.78, 0.11]
2.2 Individual intervention
delivery
8 312 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.58, 0.14]
3 Fatigue post intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
3.1 Monodisciplinary
intervention type
9 452 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.44, 0.04]
3.2 Multi-disciplinary
intervention type
3 83 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.30, 0.47]
4 Fatigue post intervention 12 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.50, 0.00]
4.1 Fatigue-specific
intervention aim
5 232 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.48, 0.31]
4.2 Other intervention aim 7 303 Std. Mean Difference (IV, Random, 95% CI) -0.37 [-0.72, -0.02]
5 Fatigue first follow-up 7 270 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.78, -0.28]
5.1 No additional sessions 4 147 Std. Mean Difference (IV, Random, 95% CI) -0.66 [1.00, -0.32]
5.2 Additional sessions 3 123 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.90, 0.04]
6 Fatigue second follow-up 5 202 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.58, 0.07]
6.1 No additional sessions 2 91 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.12, 0.30]
6.2 Additional sessions 3 111 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.74, 0.30]
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Comparison 8. Sensitivity analyses




participants Statistical method Effect size
1 Fatigue post intervention 9 476 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.59, 0.00]
2 Fatigue first follow-up 1 103 Std. Mean Difference (IV, Random, 95% CI) -0.70 [-1.10, -0.30]
3 Fatigue second follow-up 1 81 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-0.67, 0.22]
Analysis 1.1. Comparison 1 Fatigue, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 1 Fatigue












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armes 2007 6 55.67 (10.48) 10 58.2 (23.93) 4.7 % -0.12 [ -1.13, 0.89 ]
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 6.5 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 7.5 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 14.0 % -0.57 [ -0.95, -0.19 ]
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 12.5 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 13.3 % -0.14 [ -0.55, 0.27 ]
Johansson 2008 19 31.58 (25.19) 9 30.86 (28.75) 6.7 % 0.03 [ -0.77, 0.82 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 6.8 % -0.22 [ -1.01, 0.57 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 7.6 % -1.22 [ -1.94, -0.50 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 5.7 % -1.13 [ -2.02, -0.24 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 10.1 % 0.14 [ -0.42, 0.70 ]
Walker 2014 8 73.61 (23.71) 7 71.43 (31.33) 4.7 % 0.07 [ -0.94, 1.09 ]
Total (95% CI) 272 263 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.47, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Fatigue, Outcome 2 First follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 1 Fatigue












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armes 2007 4 47.25 (5.85) 4 67.5 (19.14) 4.3 % -1.24 [ -2.87, 0.38 ]
Barsevick 2004 6 2 (0.74) 11 2.65 (1.13) 10.9 % -0.61 [ -1.63, 0.41 ]
Chan 2011 53 3.28 (2.71) 50 5.29 (2.97) 71.8 % -0.70 [ -1.10, -0.30 ]
Johansson 2008 12 33.33 (29.96) 7 41.27 (28.48) 13.0 % -0.26 [ -1.19, 0.68 ]
Total (95% CI) 75 72 100.0 % -0.66 [ -1.00, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00014)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Fatigue, Outcome 3 Second follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 1 Fatigue










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armes 2007 4 28 (32.06) 6 61 (22.74) 20.7 % -1.12 [ -2.53, 0.29 ]
Chan 2011 47 3.63 (2.89) 34 4.28 (2.8) 79.3 % -0.23 [ -0.67, 0.22 ]
Total (95% CI) 51 40 100.0 % -0.41 [ -1.12, 0.30 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Physical functioning, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 2 Physical functioning












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barsevick 2010 15 35.77 (10.2) 14 37.79 (11.69) 12.8 % -0.18 [ -0.91, 0.55 ]
Bordeleau 2003 44 61.82 (25.81) 16 65 (23.66) 17.4 % -0.12 [ -0.70, 0.45 ]
Chan 2011 53 68.87 (26.07) 57 47.54 (33.21) 25.6 % 0.71 [ 0.32, 1.09 ]
Johansson 2008 19 80 (18.86) 9 73.33 (28.28) 11.2 % 0.29 [ -0.51, 1.09 ]
Savard 2006 13 69.23 (26.6) 12 60 (29.54) 11.4 % 0.32 [ -0.47, 1.11 ]
Sharpe 2014 13 69.74 (20.66) 27 52.1 (24.39) 13.9 % 0.74 [ 0.06, 1.43 ]
Walker 2014 8 41.67 (16.23) 7 37.14 (31.24) 7.7 % 0.18 [ -0.84, 1.19 ]
Total (95% CI) 165 142 100.0 % 0.32 [ 0.01, 0.63 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 9.29, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Physical functioning, Outcome 2 First follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 2 Physical functioning










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chan 2011 53 67.45 (27.73) 50 50.7 (33.01) 72.2 % 0.55 [ 0.15, 0.94 ]
Johansson 2008 12 77.5 (25.63) 7 80 (20) 27.8 % -0.10 [ -1.03, 0.83 ]
Total (95% CI) 65 57 100.0 % 0.37 [ -0.20, 0.94 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Usual care Psychosocial intervention
Analysis 3.1. Comparison 3 Social functioning, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 3 Social functioning










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bordeleau 2003 42 63.89 (23.83) 16 75 (26.53) 32.6 % -11.11 [ -25.97, 3.75 ]
Johansson 2008 19 85.96 (19.45) 9 75.93 (26.5) 26.8 % 10.03 [ -9.37, 29.43 ]
Sharpe 2014 13 69.23 (31.8) 27 48.15 (35) 24.2 % 21.08 [ -0.67, 42.83 ]
Walker 2014 8 62.5 (36.46) 7 62.5 (23) 16.5 % 0.0 [ -30.47, 30.47 ]
Total (95% CI) 82 59 100.0 % 4.16 [ -11.20, 19.53 ]
Heterogeneity: Tau2 = 131.28; Chi2 = 6.62, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Role functioning, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 4 Role functioning










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bordeleau 2003 44 53.41 (37.97) 16 59.38 (20.16) 35.0 % -5.97 [ -20.92, 8.98 ]
Johansson 2008 19 71.05 (34.62) 9 77.78 (36.32) 19.8 % -6.73 [ -35.11, 21.65 ]
Sharpe 2014 13 65.38 (25.88) 27 41.98 (34.08) 29.5 % 23.40 [ 4.34, 42.46 ]
Walker 2014 8 45.83 (29.21) 7 45.83 (36.91) 15.7 % 0.0 [ -34.02, 34.02 ]
Total (95% CI) 84 59 100.0 % 3.49 [ -12.78, 19.76 ]
Heterogeneity: Tau2 = 138.66; Chi2 = 6.27, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Emotional functioning, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 5 Emotional functioning












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barsevick 2010 15 50.41 (8.11) 14 54.21 (5.64) 29.9 % -0.53 [ -1.27, 0.22 ]
Bordeleau 2003 42 68.45 (19.61) 16 70.83 (26.18) 43.5 % -0.11 [ -0.69, 0.47 ]
Johansson 2008 19 83.77 (17.45) 9 76.85 (18.99) 26.6 % 0.37 [ -0.43, 1.17 ]
Total (95% CI) 76 39 100.0 % -0.11 [ -0.56, 0.35 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 2.61, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Cognitive functioning, Outcome 1 Post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 6 Cognitive functioning










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bordeleau 2003 42 72.22 (20.71) 16 79.17 (20.64) 55.3 % -6.95 [ -18.85, 4.95 ]
Johansson 2008 19 85.09 (16.57) 9 81.48 (17.57) 44.7 % 3.61 [ -10.07, 17.29 ]
Total (95% CI) 61 25 100.0 % -2.23 [ -12.52, 8.06 ]
Heterogeneity: Tau2 = 12.96; Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Subgroup analyses, Outcome 1 Fatigue post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Short intervention duration
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 6.5 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 7.5 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 14.0 % -0.57 [ -0.95, -0.19 ]
Subtotal (95% CI) 78 85 27.9 % -0.12 [ -0.72, 0.48 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 5.51, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.39 (P = 0.69)
2 Intermediate-long intervention duration
Armes 2007 6 55.67 (10.48) 10 58.2 (23.93) 4.7 % -0.12 [ -1.13, 0.89 ]
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 12.5 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 13.3 % -0.14 [ -0.55, 0.27 ]
Johansson 2008 19 31.58 (25.19) 9 30.86 (28.75) 6.7 % 0.03 [ -0.77, 0.82 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 6.8 % -0.22 [ -1.01, 0.57 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 7.6 % -1.22 [ -1.94, -0.50 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 5.7 % -1.13 [ -2.02, -0.24 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 10.1 % 0.14 [ -0.42, 0.70 ]
Walker 2014 8 73.61 (23.71) 7 71.43 (31.33) 4.7 % 0.07 [ -0.94, 1.09 ]
Subtotal (95% CI) 194 178 72.1 % -0.28 [ -0.57, 0.02 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 13.84, df = 8 (P = 0.09); I2 =42%
Test for overall effect: Z = 1.83 (P = 0.068)
Total (95% CI) 272 263 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.47, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 7.2. Comparison 7 Subgroup analyses, Outcome 2 Fatigue post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group intervention delivery
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 13.2 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 14.0 % -0.14 [ -0.55, 0.27 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 6.2 % -1.13 [ -2.02, -0.24 ]
Subtotal (95% CI) 101 94 33.4 % -0.33 [ -0.78, 0.11 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.12, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Individual intervention delivery
Armes 2007 6 55.67 (10.48) 10 58.2 (23.93) 5.2 % -0.12 [ -1.13, 0.89 ]
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 7.0 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 8.1 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 14.7 % -0.57 [ -0.95, -0.19 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 7.4 % -0.22 [ -1.01, 0.57 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 8.3 % -1.22 [ -1.94, -0.50 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 10.8 % 0.14 [ -0.42, 0.70 ]
Walker 2014 8 73.61 (23.71) 7 71.43 (31.33) 5.2 % 0.07 [ -0.94, 1.09 ]
Subtotal (95% CI) 152 160 66.6 % -0.22 [ -0.58, 0.14 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 14.79, df = 7 (P = 0.04); I2 =53%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 253 254 100.0 % -0.27 [ -0.53, 0.00 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 18.94, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 7.3. Comparison 7 Subgroup analyses, Outcome 3 Fatigue post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Monodisciplinary intervention type
Armes 2007 6 55.67 (10.48) 10 58.2 (23.93) 4.7 % -0.12 [ -1.13, 0.89 ]
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 6.5 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 7.5 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 14.0 % -0.57 [ -0.95, -0.19 ]
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 12.5 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 13.3 % -0.14 [ -0.55, 0.27 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 6.8 % -0.22 [ -1.01, 0.57 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 5.7 % -1.13 [ -2.02, -0.24 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 10.1 % 0.14 [ -0.42, 0.70 ]
Subtotal (95% CI) 232 220 81.0 % -0.20 [ -0.44, 0.04 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 11.59, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Multi-disciplinary intervention type
Johansson 2008 19 31.58 (25.19) 9 30.86 (28.75) 6.7 % 0.03 [ -0.77, 0.82 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 7.6 % -1.22 [ -1.94, -0.50 ]
Walker 2014 8 73.61 (23.71) 7 71.43 (31.33) 4.7 % 0.07 [ -0.94, 1.09 ]
Subtotal (95% CI) 40 43 19.0 % -0.41 [ -1.30, 0.47 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 6.75, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 272 263 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.47, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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Analysis 7.4. Comparison 7 Subgroup analyses, Outcome 4 Fatigue post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Fatigue-specific intervention aim
Armes 2007 6 55.67 (10.48) 10 58.2 (23.93) 4.7 % -0.12 [ -1.13, 0.89 ]
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 6.5 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 7.5 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 14.0 % -0.57 [ -0.95, -0.19 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 10.1 % 0.14 [ -0.42, 0.70 ]
Subtotal (95% CI) 118 114 42.7 % -0.09 [ -0.48, 0.31 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 7.38, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Other intervention aim
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 12.5 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 13.3 % -0.14 [ -0.55, 0.27 ]
Johansson 2008 19 31.58 (25.19) 9 30.86 (28.75) 6.7 % 0.03 [ -0.77, 0.82 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 6.8 % -0.22 [ -1.01, 0.57 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 7.6 % -1.22 [ -1.94, -0.50 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 5.7 % -1.13 [ -2.02, -0.24 ]
Walker 2014 8 73.61 (23.71) 7 71.43 (31.33) 4.7 % 0.07 [ -0.94, 1.09 ]
Subtotal (95% CI) 154 149 57.3 % -0.37 [ -0.72, -0.02 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 2.05 (P = 0.041)
Total (95% CI) 272 263 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.47, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 1.08, df = 1 (P = 0.30), I2 =7%
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Analysis 7.5. Comparison 7 Subgroup analyses, Outcome 5 Fatigue first follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 No additional sessions
Armes 2007 4 47.25 (5.85) 4 67.5 (19.14) 2.3 % -1.24 [ -2.87, 0.38 ]
Barsevick 2004 6 2 (0.74) 11 2.65 (1.13) 5.9 % -0.61 [ -1.63, 0.41 ]
Chan 2011 53 3.28 (2.71) 50 5.29 (2.97) 38.9 % -0.70 [ -1.10, -0.30 ]
Johansson 2008 12 33.33 (29.96) 7 41.27 (28.48) 7.1 % -0.26 [ -1.19, 0.68 ]
Subtotal (95% CI) 75 72 54.2 % -0.66 [ -1.00, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00014)
2 Additional sessions
Edelman 1999 36 9.44 (7.37) 37 10.62 (8.61) 29.3 % -0.15 [ -0.61, 0.31 ]
Sharpe 2014 12 44.44 (20.65) 27 63.79 (23.79) 12.4 % -0.83 [ -1.53, -0.12 ]
Walker 2014 6 68.52 (14.77) 5 80 (18.26) 4.1 % -0.64 [ -1.87, 0.59 ]
Subtotal (95% CI) 54 69 45.8 % -0.43 [ -0.90, 0.04 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.71, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.79 (P = 0.074)
Total (95% CI) 129 141 100.0 % -0.53 [ -0.78, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.21, df = 6 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
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Analysis 7.6. Comparison 7 Subgroup analyses, Outcome 6 Fatigue second follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 7 Subgroup analyses










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 No additional sessions
Armes 2007 4 28 (32.06) 6 61 (22.74) 5.1 % -1.12 [ -2.53, 0.29 ]
Chan 2011 47 3.63 (2.89) 34 4.28 (2.8) 37.4 % -0.23 [ -0.67, 0.22 ]
Subtotal (95% CI) 51 40 42.4 % -0.41 [ -1.12, 0.30 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Additional sessions
Edelman 1999 30 9.7 (6.91) 33 9.36 (8.08) 31.9 % 0.04 [ -0.45, 0.54 ]
Sharpe 2014 12 50.93 (23.43) 23 67.15 (20.51) 17.4 % -0.74 [ -1.46, -0.01 ]
Walker 2014 7 68.25 (26.78) 6 68.52 (33.27) 8.3 % -0.01 [ -1.10, 1.08 ]
Subtotal (95% CI) 49 62 57.6 % -0.22 [ -0.74, 0.30 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 3.17, df = 2 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 100 102 100.0 % -0.26 [ -0.58, 0.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 4.75, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 8.1. Comparison 8 Sensitivity analyses, Outcome 1 Fatigue post intervention.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 8 Sensitivity analyses












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barsevick 2004 10 3.02 (1.43) 14 2.74 (1.11) 8.2 % 0.22 [ -0.60, 1.03 ]
Barsevick 2010 15 2.96 (1.04) 14 2.67 (1.37) 9.3 % 0.23 [ -0.50, 0.96 ]
Chan 2011 53 3.45 (2.7) 57 5.07 (2.93) 15.7 % -0.57 [ -0.95, -0.19 ]
Classen 2001 47 9.57 (6.43) 33 10.85 (8.25) 14.3 % -0.18 [ -0.62, 0.27 ]
Edelman 1999 43 9.33 (6.6) 49 10.39 (8.3) 15.1 % -0.14 [ -0.55, 0.27 ]
Savard 2006 13 44.77 (11.16) 12 47.33 (11.26) 8.5 % -0.22 [ -1.01, 0.57 ]
Sharpe 2014 13 36.75 (19.97) 27 64.61 (23.48) 9.5 % -1.22 [ -1.94, -0.50 ]
Spiegel 1981 11 5.55 (4.46) 12 12.64 (7.19) 7.3 % -1.13 [ -2.02, -0.24 ]
Steel 2016 34 20.15 (7.82) 19 18.95 (9.6) 12.1 % 0.14 [ -0.42, 0.70 ]
Total (95% CI) 239 237 100.0 % -0.30 [ -0.59, 0.00 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 18.35, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Sensitivity analyses, Outcome 2 Fatigue first follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 8 Sensitivity analyses










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chan 2011 53 3.28 (2.71) 50 5.29 (2.97) 100.0 % -0.70 [ -1.10, -0.30 ]
Total (95% CI) 53 50 100.0 % -0.70 [ -1.10, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00055)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Sensitivity analyses, Outcome 3 Fatigue second follow-up.
Review: Psychosocial interventions for fatigue during cancer treatment with palliative intent
Comparison: 8 Sensitivity analyses










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chan 2011 47 3.63 (2.89) 34 4.28 (2.8) 100.0 % -0.23 [ -0.67, 0.22 ]
Total (95% CI) 47 34 100.0 % -0.23 [ -0.67, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. GRADE system
The GRADE system uses the following criteria for assigning grades of evidence:
High: We are very confident that the true effect lies close to the estimate of effect.
Moderate: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect but may be
substantially different.
Low: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of effect.
Very low: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of
effect.
The grade of evidence is decreased further if the following are present.
• Serious (-1) or very serious (-2) limitation to study quality.
• Important inconsistency (-1).
• Some (-1) or major (-2) uncertainty about directness.
• Imprecise or sparse data (-1).
• High probability of reporting bias (-1).
The grade of evidence may be increased if:
• strong evidence of association: significant relative risk > 2 (< 0.5) based on consistent evidence from two or more observational
studies, with no plausible confounders (+1);
• very strong evidence of association: significant relative risk > 5 (< 0.2) based on direct evidence with no major threats to validity
(+2);
• evidence of a dose-response gradient (+1); or
• all plausible confounders would have reduced the effect (+1).
Appendix 2. CENTRAL search strategy
#1 ((neoplas* or cancer*)):TI,AB,KY
#2 (carcinoma* or tumour* or adenocarcinoma*):TI,AB,KY
#3 (leukemi* or leukaemia* or lymphoma*):TI,AB,KY
#4 (tumor* or malignan* or melanoma* or sarcoma*):TI,AB,KY
#5 (“bone marrow transplant*” or “stem cell transplant*”):TI,AB,KY
#6 MESH DESCRIPTOR Neoplasms EXPLODE ALL TREES
#7 MESH DESCRIPTOR Bone Marrow Transplantation
#8 MESH DESCRIPTOR Stem Cell Transplantation EXPLODE ALL TREES
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 MESH DESCRIPTOR Fatigue EXPLODE ALL TREES
#11 ((fatigue* or asthenia or asthenic or astheni*)):TI,AB,KY
#12 ((exhaustion or exhausted)):TI,AB,KY
#13 (((loss adj4 energy) or (loss adj4 vitality))):TI,AB,KY
#14 ((weary or weariness or weakness)):TI,AB,KY
#15 ((apathy or apathetic or lassitude or lethargic or lethargy)):TI,AB,KY
#16 ((sleepy or sleepiness or drowsy or drowsiness)):TI,AB,KY
#17 ((tired or tiredness)):TI,AB,KY
#18 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 MESH DESCRIPTOR Psychotherapy EXPLODE ALL TREES
#20 ((psychosocial* or psycho-social*)):TI,AB,KY
#21 management“ or psychotherapy* or ”self
#22 educati* or psychoeducat* or relaxation
#23 counsel$ or (behaviour$ adj4 therap$) or “autogenic training”
#24 (behavior* adj4 therap*) or (relax* adj4 therap*) or (relax* adj4 treatment*) or (support* adj4 group*)
#25 management“ or psychotherapy* or ”self
66Psychosocial interventions for fatigue during cancer treatment with palliative intent (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#26 imagery or “energy conservation” or “stress management” or psychotherapy* or “self care” or “self help”
#27 “nursing support”
#28 biofeedback or educati* or psychoeducat* or relaxation therap*
#29 “nursing intervention” or “nursing support”
#30 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
#31 #9 AND #18 AND #30
Appendix 3. MEDLINE search strategy
1 exp Neoplasms/
2 Bone Marrow Transplantation/
3 exp Stem Cell Transplantation/
4 (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ or lymphoma$ or tumor$ or
malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” or “stem cell transplant$”).mp.
5 or/1-4
6 exp Fatigue/
7 (fatigue$ or asthenia or asthenic or astheni$).mp.
8 (exhaustion or exhausted).mp.
9 ((loss adj4 energy) or (loss adj4 vitality)).mp.
10 (weary or weariness or weakness).mp.
11 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
12 (sleepy or sleepiness or drowsy or drowsiness).mp.
13 (tired or tiredness).mp.
14 or/6-13
15 exp Psychotherapy/
16 (psychosocial$ or psycho-social$).mp.
17 (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) or (relax$ adj4 therap$) or (relax$ adj4
treatment$) or (support$ adj4 group$) or imagery or “energy conservation” or “stress management” or psychotherapy$ or “self care”
or “self help” or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or “nursing support”).mp.
18 or/15-17
19 5 and 14 and 18
20 randomized controlled trial.pt.







28 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 exp animals/ not humans.sh.
30 28 not 29
31 19 and 30
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Appendix 4. Embase search strategy
1 exp Neoplasms/
2 Bone Marrow Transplantation/
3 exp Stem Cell Transplantation/
4 (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ or lymphoma$ or tumor$ or
malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” or “stem cell transplant$”).mp.
5 or/1-4
6 exp Fatigue/
7 (fatigue$ or asthenia or asthenic or astheni$).mp.
8 (exhaustion or exhausted).mp.
9 ((loss adj4 energy) or (loss adj4 vitality)).mp.
10 (weary or weariness or weakness).mp.
11 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
12 (sleepy or sleepiness or drowsy or drowsiness).mp.
13 (tired or tiredness).mp.
14 or/6-13
15 exp Psychotherapy/
16 (psychosocial$ or psycho-social$).mp.
17 (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) or (relax$ adj4 therap$) or (relax$ adj4
treatment$) or (support$ adj4 group$) or imagery or “energy conservation” or “stress management” or psychotherapy$ or “self care”
or “self help” or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or “nursing support”).mp.
18 or/15-17







26 (doubl$ adj blind$).tw.




31 Crossover Procedure/ (45499)
32 double-blind procedure.tw. (229)
33 Randomized Controlled Trial/ (391636)
34 Single Blind Procedure/ (21265)
35 or/20-34 (1643586)
36 (animal/ or nonhuman/) not human/ (4924135)
37 35 not 36 (1458151)
38 19 and 37 (956)
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Appendix 5. CINAHL search strategy
S28 S18 AND S27
S27 S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26
S26 (allocat* random*)




S21 (MH “Random Assignment”)
S20 (Randomi?ed control* trial*)
S19 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S18 S5 AND S13 AND S17
S17 S14 OR S15 OR S16
S16 (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior* N4 therap*) or (relax* N4 therap*) or (relax* N4
treatment*) or (support* N4 group*) or imagery or “energy conservation” or “stress management” or psychotherapy* or “self care” or
“self help” or biofeedback or educati* or psychoeducat* or relaxation therap* or “nursing intervention” or “nursing support”)
S15 psychosocial* or psycho-social*
S14 (MH “Psychotherapy+”)
S13 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 tired or tiredness
S11 sleepy or sleepiness or drowsy or drowsiness
S10 apathy or apathetic or lassitude or lethargic or lethargy
S9 weary or weariness or weakness
S8 (loss N4 energy) or (loss N4 vitality)
S7 exhaustion or exhausted
S6 (fatigue* or asthenia or asthenic or astheni*)
S5 S1 OR S2 OR S3 OR S4
S4 (neoplas* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemia* or lymphoma* or tumor* ormalignan*
or melanoma* or sarcoma* or “bone marrow transplant*” or “stem cell transplant*”)
S3 (MH “Hematopoietic Stem Cell Transplantation”)
S2 (MH “Bone Marrow Transplantation”)
S1 (MH “Neoplasms”)
Appendix 6. PsycINFO search strategy
1 exp Neoplasms/
2 (neoplas$ or cancer$ or carcinoma$ or tumour$ or adenocarcinoma$ or leukemi$ or leukaemia$ or lymphoma$ or tumor$ or
malignan$ or melanoma$ or sarcoma$ or “bone marrow transplant$” or “stem cell transplant$”).mp.
3 exp Fatigue/
4 (fatigue$ or asthenia or asthenic or astheni$).mp.
5 (exhaustion or exhausted).mp.
6 ((loss adj4 energy) or (loss adj4 vitality)).mp.
7 (weary or weariness or weakness).mp.
8 (apathy or apathetic or lassitude or lethargic or lethargy).mp.
9 (sleepy or sleepiness or drowsy or drowsiness).mp.
10 (tired or tiredness).mp.
11 or/3-10
12 exp Psychotherapy/
13 (psychosocial$ or psycho-social$).mp.
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14 (counsel$ or (behaviour$ adj4 therap$) or “autogenic training” or (behavior$ adj4 therap$) or (relax$ adj4 therap$) or (relax$ adj4
treatment$) or (support$ adj4 group$) or imagery or “energy conservation” or “stress management” or psychotherapy$ or “self care”
or “self help” or biofeedback or educati$ or psychoeducat$ or relaxation therap$ or “nursing intervention” or “nursing support”).mp.
15 or/12-14
16 1 or 2
17 11 and 15 and 16
18 clinical trials/
19 (randomis* or randomiz*).tw.
20 (random$ adj3 (allocat$ or assign$)).tw.
21 ((clinic$ or control$) adj trial$).tw.
22 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.





28 exp program evaluation/
29 treatment effectiveness evaluation/
30 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
31 or/18-30
32 17 and 31
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• Dutch Cancer Society, Netherlands.
Funding
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The final review differs from the protocol in five ways. First, we originally intended to select only participants with a diagnosis of
incurable cancer whowere receiving some form of active cancer treatment. However, several original study investigators of mixed-sample
studies did not respond to our request for subset data or were unable to select the subset of those participants. In those instances, we
included studies when the sample involved more than 80% of participants with incurable cancer receiving some form of active cancer
treatment. Second, we planned to use fixed-effect models in all meta-analyses for this review. However, patient populations were quite
variable in cancer diagnosis and treatment (as were the interventions); thus we employed random-effects models. Third, we originally
used the overall term ’measures of function’ in our protocol to reflect physical, social, role, emotional, and cognitive functioning as
secondary outcomes of this review. In the final review, we have defined this outcome more clearly and have changed our wording to all
five individual domains instead of using an overall term. Fourth, we did not include different time points for outcomes in the protocol.
Yet, some studies reported outcomes not only for post-intervention assessment but also for one or two follow-up assessments. We
aimed to be as complete as possible in reporting our findings and thus also included fatigue and physical functioning data for first and
second follow-up as secondary outcomes. Last, we added a subgroup analyses to the review to examine follow-up effects for studies that
included additional (booster) sessions between post-intervention assessment and follow-up versus studies without additional sessions.
We did not foresee in the protocol the use of additional (booster) sessions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Activities of Daily Living; Cognition; Fatigue [etiology; physiopathology; psychology; ∗therapy]; Neoplasms [∗complications; phys-
iopathology; psychology; therapy]; Palliative Care [∗methods]; Psychotherapy [∗methods]; Quality of Life; Randomized Controlled
Trials as Topic; Social Skills
MeSH check words
Adult; Female; Humans; Male; Middle Aged
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